101
|
Zuber V, Bettella F, Witoelar A, Andreassen OA, Mills IG, Urbanucci A. Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics 2017; 18:270. [PMID: 28359301 PMCID: PMC5374680 DOI: 10.1186/s12864-017-3620-y] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2016] [Accepted: 03/11/2017] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND Epigenetic information can be used to identify clinically relevant genomic variants single nucleotide polymorphisms (SNPs) of functional importance in cancer development. Super-enhancers are cell-specific DNA elements, acting to determine tissue or cell identity and driving tumor progression. Although previous approaches have been tried to explain risk associated with SNPs in regulatory DNA elements, so far epigenetic readers such as bromodomain containing protein 4 (BRD4) and super-enhancers have not been used to annotate SNPs. In prostate cancer (PC), androgen receptor (AR) binding sites to chromatin have been used to inform functional annotations of SNPs. RESULTS Here we establish criteria for enhancer mapping which are applicable to other diseases and traits to achieve the optimal tissue-specific enrichment of PC risk SNPs. We used stratified Q-Q plots and Fisher test to assess the differential enrichment of SNPs mapping to specific categories of enhancers. We find that BRD4 is the key discriminant of tissue-specific enhancers, showing that it is more powerful than AR binding information to capture PC specific risk loci, and can be used with similar effect in breast cancer (BC) and applied to other diseases such as schizophrenia. CONCLUSIONS This is the first study to evaluate the enrichment of epigenetic readers in genome-wide associations studies for SNPs within enhancers, and provides a powerful tool for enriching and prioritizing PC and BC genetic risk loci. Our study represents a proof of principle applicable to other diseases and traits that can be used to redefine molecular mechanisms of human phenotypic variation.
Collapse
Affiliation(s)
- Verena Zuber
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
| | - Francesco Bettella
- NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - Aree Witoelar
- NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - the CRUK GWAS
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- PCUK Movember Centre of Excellence, CCRCB, Queen’s University, Belfast, UK
| | - the TRICL Consortium
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo, Oslo, Norway
- NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
- European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- PCUK Movember Centre of Excellence, CCRCB, Queen’s University, Belfast, UK
| | - Ole A. Andreassen
- NORMENT, KG Jebsen Centre for Psychosis Research, Institute of Clinical Medicine, University of Oslo, Oslo, Norway
- Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
| | - Ian G. Mills
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
- PCUK Movember Centre of Excellence, CCRCB, Queen’s University, Belfast, UK
| | - Alfonso Urbanucci
- Prostate Cancer Research Group, Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo, Oslo, Norway
- Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
102
|
Rosenberger A, Sohns M, Friedrichs S, Hung RJ, Fehringer G, McLaughlin J, Amos CI, Brennan P, Risch A, Brüske I, Caporaso NE, Landi MT, Christiani DC, Wei Y, Bickeböller H. Gene-set meta-analysis of lung cancer identifies pathway related to systemic lupus erythematosus. PLoS One 2017; 12:e0173339. [PMID: 28273134 PMCID: PMC5342225 DOI: 10.1371/journal.pone.0173339] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Accepted: 02/20/2017] [Indexed: 02/03/2023] Open
Abstract
INTRODUCTION Gene-set analysis (GSA) is an approach using the results of single-marker genome-wide association studies when investigating pathways as a whole with respect to the genetic basis of a disease. METHODS We performed a meta-analysis of seven GSAs for lung cancer, applying the method META-GSA. Overall, the information taken from 11,365 cases and 22,505 controls from within the TRICL/ILCCO consortia was used to investigate a total of 234 pathways from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database. RESULTS META-GSA reveals the systemic lupus erythematosus KEGG pathway hsa05322, driven by the gene region 6p21-22, as also implicated in lung cancer (p = 0.0306). This gene region is known to be associated with squamous cell lung carcinoma. The most important genes driving the significance of this pathway belong to the genomic areas HIST1-H4L, -1BN, -2BN, -H2AK, -H4K and C2/C4A/C4B. Within these areas, the markers most significantly associated with LC are rs13194781 (located within HIST12BN) and rs1270942 (located between C2 and C4A). CONCLUSIONS We have discovered a pathway currently marked as specific to systemic lupus erythematosus as being significantly implicated in lung cancer. The gene region 6p21-22 in this pathway appears to be more extensively associated with lung cancer than previously assumed. Given wide-stretched linkage disequilibrium to the area APOM/BAG6/MSH5, there is currently simply not enough information or evidence to conclude whether the potential pleiotropy of lung cancer and systemic lupus erythematosus is spurious, biological, or mediated. Further research into this pathway and gene region will be necessary.
Collapse
Affiliation(s)
- Albert Rosenberger
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Melanie Sohns
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Stefanie Friedrichs
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | - Gord Fehringer
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada
| | | | - Christopher I. Amos
- Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire, United States of America
| | - Paul Brennan
- International Agency for Research on Cancer, Lyon, France
| | - Angela Risch
- Division of Molecular Biology, University Salzburg, Salzburg, Austria
| | - Irene Brüske
- Institute of Epidemiology I, Helmholtz Center Munich, Munich, Germany
| | - Neil E. Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - David C. Christiani
- Harvard University School of Public Health, Boston, Massachusetts, United States of America
| | - Yongyue Wei
- Harvard University School of Public Health, Boston, Massachusetts, United States of America
| | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| |
Collapse
|
103
|
Genetic susceptibility variants for lung cancer: replication study and assessment as expression quantitative trait loci. Sci Rep 2017; 7:42185. [PMID: 28181565 PMCID: PMC5299838 DOI: 10.1038/srep42185] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2016] [Accepted: 01/06/2017] [Indexed: 12/13/2022] Open
Abstract
Many single nucleotide polymorphisms (SNPs) have been associated with lung cancer but lack confirmation and functional characterization. We retested the association of 56 candidate SNPs with lung adenocarcinoma risk and overall survival in a cohort of 823 Italian patients and 779 healthy controls, and assessed their function as expression quantitative trait loci (eQTLs). In the replication study, eight SNPs (rs401681, rs3019885, rs732765, rs2568494, rs16969968, rs6495309, rs11634351, and rs4105144) associated with lung adenocarcinoma risk and three (rs9557635, rs4105144, and rs735482) associated with survival. Five of these SNPs acted as cis-eQTLs, being associated with the transcription of IREB2 (rs2568494, rs16969968, rs11634351, rs6495309), PSMA4 (rs6495309) and ERCC1 (rs735482), out of 10,821 genes analyzed in lung. For these three genes, we obtained experimental evidence of differential allelic expression in lung tissue, pointing to the existence of in-cis genomic variants that regulate their transcription. These results suggest that these SNPs exert their effects on cancer risk/outcome through the modulation of mRNA levels of their target genes.
Collapse
|
104
|
Musolf AM, Simpson CL, de Andrade M, Mandal D, Gaba C, Yang P, Li Y, You M, Kupert EY, Anderson MW, Schwartz AG, Pinney SM, Amos CI, Bailey-Wilson JE. Familial Lung Cancer: A Brief History from the Earliest Work to the Most Recent Studies. Genes (Basel) 2017; 8:genes8010036. [PMID: 28106732 PMCID: PMC5295030 DOI: 10.3390/genes8010036] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2016] [Revised: 12/29/2016] [Accepted: 01/11/2017] [Indexed: 02/06/2023] Open
Abstract
Lung cancer is the deadliest cancer in the United States, killing roughly one of four cancer patients in 2016. While it is well-established that lung cancer is caused primarily by environmental effects (particularly tobacco smoking), there is evidence for genetic susceptibility. Lung cancer has been shown to aggregate in families, and segregation analyses have hypothesized a major susceptibility locus for the disease. Genetic association studies have provided strong evidence for common risk variants of small-to-moderate effect. Rare and highly penetrant alleles have been identified by linkage studies, including on 6q23-25. Though not common, some germline mutations have also been identified via sequencing studies. Ongoing genomics studies aim to identify additional high penetrance germline susceptibility alleles for this deadly disease.
Collapse
Affiliation(s)
- Anthony M Musolf
- National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA.
| | - Claire L Simpson
- National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA.
- Department of Genetics, Genomics and Informatics, University of Tennessee Health Science Center, Memphis, TN 38103, USA.
| | | | - Diptasri Mandal
- Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA.
| | - Colette Gaba
- Department of Medicine, University of Toledo Dana Cancer Center, Toledo, OH 43604, USA.
| | - Ping Yang
- Mayo Clinic, Rochester, MN 55904, USA.
| | - Yafang Li
- Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA.
| | - Ming You
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53202, USA.
| | - Elena Y Kupert
- Cancer Center, Medical College of Wisconsin, Milwaukee, WI 53202, USA.
| | | | - Ann G Schwartz
- Karmanos Cancer Institute, Wayne State University, Detroit, MI 48226, USA.
| | - Susan M Pinney
- Department of Environmental Health, University of Cincinnati College of Medicine, Cincinnati, OH 45202, USA.
| | | | - Joan E Bailey-Wilson
- National Human Genome Research Institute, National Institutes of Health, Baltimore, MD 21224, USA.
| |
Collapse
|
105
|
Seow WJ, Matsuo K, Hsiung CA, Shiraishi K, Song M, Kim HN, Wong MP, Hong YC, Hosgood HD, Wang Z, Chang IS, Wang JC, Chatterjee N, Tucker M, Wei H, Mitsudomi T, Zheng W, Kim JH, Zhou B, Caporaso NE, Albanes D, Shin MH, Chung LP, An SJ, Wang P, Zheng H, Yatabe Y, Zhang XC, Kim YT, Shu XO, Kim YC, Bassig BA, Chang J, Ho JCM, Ji BT, Kubo M, Daigo Y, Ito H, Momozawa Y, Ashikawa K, Kamatani Y, Honda T, Sakamoto H, Kunitoh H, Tsuta K, Watanabe SI, Nokihara H, Miyagi Y, Nakayama H, Matsumoto S, Tsuboi M, Goto K, Yin Z, Shi J, Takahashi A, Goto A, Minamiya Y, Shimizu K, Tanaka K, Wu T, Wei F, Wong JY, Matsuda F, Su J, Kim YH, Oh IJ, Song F, Lee VHF, Su WC, Chen YM, Chang GC, Chen KY, Huang MS, Yang PC, Lin HC, Xiang YB, Seow A, Park JY, Kweon SS, Chen CJ, Li H, Gao YT, Wu C, Qian B, Lu D, Liu J, Jeon HS, Hsiao CF, Sung JS, Tsai YH, Jung YJ, Guo H, Hu Z, Wang WC, Chung CC, Lawrence C, Burdett L, Yeager M, Jacobs KB, Hutchinson A, Berndt SI, He X, Wu W, Wang J, Li Y, Choi JE, Park KH, Sung SW, Liu L, Kang CH, Hu L, Chen CH, Yang TY, Xu J, Guan P, Tan W, Wang CL, Sihoe ADL, Chen Y, Choi YY, Hung JY, Kim JS, Yoon HI, Cai Q, Lin CC, Park IK, Xu P, Dong J, Kim C, He Q, Perng RP, Chen CY, Vermeulen R, Wu J, Lim WY, Chen KC, Chan JK, Chu M, Li YJ, Li J, Chen H, Yu CJ, Jin L, Lo YL, Chen YH, Fraumeni JF, Liu J, Yamaji T, Yang Y, Hicks B, Wyatt K, Li SA, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Li X, Ren Y, Cui P, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Wu G, Chien LH, Chen HL, Su YC, Tsai FY, Chen YS, Yu J, Stevens VL, Laird-Offringa IA, Marconett CN, Lin D, Chen K, Wu YL, Landi MT, Shen H, Rothman N, Kohno T, Chanock SJ, Lan Q. Association between GWAS-identified lung adenocarcinoma susceptibility loci and EGFR mutations in never-smoking Asian women, and comparison with findings from Western populations. Hum Mol Genet 2017; 26:454-465. [PMID: 28025329 PMCID: PMC5856088 DOI: 10.1093/hmg/ddw414] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 11/29/2016] [Accepted: 12/05/2016] [Indexed: 01/12/2023] Open
Abstract
To evaluate associations by EGFR mutation status for lung adenocarcinoma risk among never-smoking Asian women, we conducted a meta-analysis of 11 loci previously identified in genome-wide association studies (GWAS). Genotyping in an additional 10,780 never-smoking cases and 10,938 never-smoking controls from Asia confirmed associations with eight known single nucleotide polymorphisms (SNPs). Two new signals were observed at genome-wide significance (P < 5 × 10-8), namely, rs7216064 (17q24.3, BPTF), for overall lung adenocarcinoma risk, and rs3817963 (6p21.3, BTNL2) which is specific to cases with EGFR mutations. In further sub-analyses by EGFR status, rs9387478 (ROS1/DCBLD1) and rs2179920 (HLA-DPB1) showed stronger estimated associations in EGFR-positive compared to EGFR-negative cases. Comparison of the overall associations with published results in Western populations revealed that the majority of these findings were distinct, underscoring the importance of distinct contributing factors for smoking and non-smoking lung cancer. Our results extend the catalogue of regions associated with lung adenocarcinoma in non-smoking Asian women and highlight the importance of how the germline could inform risk for specific tumour mutation patterns, which could have important translational implications.
Collapse
Affiliation(s)
- Wei Jie Seow
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Chao Agnes Hsiung
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Kouya Shiraishi
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
| | - Minsun Song
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Department of Statistics, Sookmyung Women’s University, Seoul, Republic of Korea
| | - Hee Nam Kim
- Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Maria Pik Wong
- Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - Yun-Chul Hong
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - H. Dean Hosgood
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
| | - Zhaoming Wang
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - I-Shou Chang
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | - Jiu-Cun Wang
- Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
| | - Nilanjan Chatterjee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Margaret Tucker
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Hu Wei
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Tetsuya Mitsudomi
- Division of Thoracic Surgery, Kinki University School of Medicine, Sayama, Japan
| | - Wei Zheng
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Jin Hee Kim
- Department of Integrative Bioscience & Biotechnology, Sejong University, Seoul, Republic of Korea
| | - Baosen Zhou
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
| | - Neil E. Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Demetrius Albanes
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Min-Ho Shin
- Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Lap Ping Chung
- Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - She-Juan An
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People’s Republic of China
| | - Ping Wang
- Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, People’s Republic of China
| | - Hong Zheng
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
| | - Yasushi Yatabe
- Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Central Hospital, Nagoya, Japan
| | - Xu-Chao Zhang
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People’s Republic of China
| | - Young Tae Kim
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Xiao-Ou Shu
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Young-Chul Kim
- Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun-eup, Republic of Korea
- Department of Internal Medicine, Chonnam National Univerisity Medical School, Gwangju, Republic of Korea
| | - Bryan A. Bassig
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Jiang Chang
- Department of Etiology & Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
| | - James Chung Man Ho
- Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong
| | - Bu-Tian Ji
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Michiaki Kubo
- Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
| | - Yataro Daigo
- Center for Antibody and Vaccine Therapy, Research Hospital, Institute of Medical Science, The University of Tokyo, Tokyo, Japan
- Department of Medical Oncology and Cancer Center, Shiga University of Medical Science, Otsu, Japan
| | - Hidemi Ito
- Division of Epidemiology & Prevention, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Yukihide Momozawa
- Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
| | - Kyota Ashikawa
- Laboratory for Genotyping Development, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
| | - Yoichiro Kamatani
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Takayuki Honda
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
| | - Hiromi Sakamoto
- Division of Genetics, National Cancer Center Research Institute, Tokyo, Japan
| | - Hideo Kunitoh
- Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan
| | - Koji Tsuta
- Department of Pathology, National Cancer Center Hospital, Tokyo, Japan
| | - Shun-Ichi Watanabe
- Division of Thoracic Surgery, National Cancer Center Hospital, Tokyo, Japan
| | - Hiroshi Nokihara
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan
| | - Yohei Miyagi
- Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute, Kanagawa, Japan
| | - Haruhiko Nakayama
- Department of Thoracic Surgery, Kanagawa Cancer Center, Kanagawa, Japan
| | - Shingo Matsumoto
- Division of Translational Research, Exploratory Oncology Research and Clinical Trial Center (EPOC), National Cancer Center, Chiba, Japan
| | - Masahiro Tsuboi
- Department of Thoracic Surgery, National Cancer Center Hospital East, Chiba, Japan
| | - Koichi Goto
- Department of Thoracic Oncology, National Cancer Center Hospital East, Japan
| | - Zhihua Yin
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
| | - Jianxin Shi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Atsushi Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | | | - Yoshihiro Minamiya
- Department of Thoracic Surgery, Graduate School of Medicine, Akita University, Akita City, Japan
| | - Kimihiro Shimizu
- Department of Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan
| | - Kazumi Tanaka
- Department of Integrative Center of General Surgery, Gunma University Hospital, Gunma, Japan
| | - Tangchun Wu
- Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
| | - Fusheng Wei
- China National Environmental Monitoring Center, Beijing, People’s Republic of China
| | - Jason Y.Y. Wong
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Fumihiko Matsuda
- Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan
| | - Jian Su
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People’s Republic of China
| | - Yeul Hong Kim
- Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
| | - In-Jae Oh
- Lung and Esophageal Cancer Clinic, Chonnam National University Hwasun Hospital, Hwasun-eup, Republic of Korea
- Department of Internal Medicine, Chonnam National Univerisity Medical School, Gwangju, Republic of Korea
| | - Fengju Song
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
| | - Victor Ho Fun Lee
- Department of Clinical Oncology, The University of Hong Kong, Queen Mary Hospital, Hong Kong
| | - Wu-Chou Su
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Yuh-Min Chen
- Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
- College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
| | - Gee-Chen Chang
- School of Medicine, Faculty of Medicine, National Yang-Ming University, Taipei, Taiwan
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Kuan-Yu Chen
- Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Ming-Shyan Huang
- Department of Internal Medicine, Kaohsiung Medical University Hospital, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Pan-Chyr Yang
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Hsien-Chih Lin
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Yong-Bing Xiang
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, People’s Republic of China
| | - Adeline Seow
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore
| | - Jae Yong Park
- Lung Cancer Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Sun-Seog Kweon
- Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
- Jeonnam Regional Cancer Center, Chonnam National University Hwasun, Hwasun Hospital, Republic of Korea
| | - Chien-Jen Chen
- Genomic Research Center, Academia Sinica, Taipei, Taiwan
| | - Haixin Li
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
| | - Yu-Tang Gao
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, People’s Republic of China
| | - Chen Wu
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
| | - Biyun Qian
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
| | - Daru Lu
- Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
| | - Jianjun Liu
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore
- Department of Human Genetics, Genome Institute of Singapore, Singapore, Singapore
- School of Life Sciences, Anhui Medical University, Hefei, People’s Republic of China
| | - Hyo-Sung Jeon
- Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Chin-Fu Hsiao
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Jae Sook Sung
- Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
| | - Ying-Huang Tsai
- Division of Pulmonary and Critical Care Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
| | - Yoo Jin Jung
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Huan Guo
- Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
| | - Zhibin Hu
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Wen-Chang Wang
- The Ph.D. Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
| | - Charles C. Chung
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | | | - Laurie Burdett
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Meredith Yeager
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Kevin B. Jacobs
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Amy Hutchinson
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Sonja I. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Xingzhou He
- Chinese Center for Disease Control and Prevention, Beijing, People’s Republic of China
| | - Wei Wu
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
| | - Junwen Wang
- Department of Health Sciences Research
- Center for Individualized Medicine, Mayo Clinic, Scottsdale, AZ, USA
| | - Yuqing Li
- Cancer Prevention Institute of California, Fremont, CA, USA
| | - Jin Eun Choi
- Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Kyong Hwa Park
- Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
| | - Sook Whan Sung
- Department of Thoracic and Cardiovascular Surgery, Seoul St Mary's Hospital, The Catholic University of Korea, Republic of Korea
| | - Li Liu
- Department of Oncology, Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, People’s Republic of China
| | - Chang Hyun Kang
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Lingmin Hu
- Ministry of Education Key Laboratory of Modern Toxicology
- Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Chung-Hsing Chen
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | - Tsung-Ying Yang
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Jun Xu
- School of Public Health, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China
| | - Peng Guan
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
- Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, People’s Republic of China
| | - Wen Tan
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
| | - Chih-Liang Wang
- Department of Pulmonary and Critical Care, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Alan Dart Loon Sihoe
- Department of Surgery, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, People’s Republic of China
| | - Ying Chen
- Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore
| | - Yi Young Choi
- Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Jen-Yu Hung
- Department of Internal Medicine, Kaohsiung Medical University Hospital, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Jun Suk Kim
- Division of Medical Oncology, Department of Internal Medicine, College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
| | - Ho-Il Yoon
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Qiuyin Cai
- Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center and Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
| | - Chien-Chung Lin
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - In Kyu Park
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Ping Xu
- Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital, Wuhan, People’s Republic of China
| | - Jing Dong
- Ministry of Education Key Laboratory of Modern Toxicology
- Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Christopher Kim
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Qincheng He
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
| | | | - Chih-Yi Chen
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
- Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan
| | - Roel Vermeulen
- Division of Environmental Epidemiology, Institute for Risk Assessment Sciences (IRAS), Utrecht University, Utrecht, The Netherlands
| | - Junjie Wu
- Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
| | | | - Kun-Chieh Chen
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | - John K.C. Chan
- Department of Pathology, Queen Elizabeth Hospital, Hong Kong, People’s Republic of China
| | - Minjie Chu
- Ministry of Education Key Laboratory of Modern Toxicology
- Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Yao-Jen Li
- Genomic Research Center, Academia Sinica, Taipei, Taiwan
| | - Jihua Li
- Qujing Center for Diseases Control and Prevention, Qujing, People’s Republic of China
| | - Hongyan Chen
- Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
| | - Chong-Jen Yu
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Li Jin
- Ministry of Education Key Laboratory of Contemporary Anthropology, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
- State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, People’s Republic of China
| | - Yen-Li Lo
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Ying-Hsiang Chen
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Joseph F. Fraumeni
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Jie Liu
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
| | - Taiki Yamaji
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan
| | - Yang Yang
- Shanghai Pulmonary Hospital, Shanghai, People’s Republic of China
| | - Belynda Hicks
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Kathleen Wyatt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Shengchao A. Li
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc, Gaithersburg, MD, USA
| | - Juncheng Dai
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Hongxia Ma
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Guangfu Jin
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Bao Song
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
| | - Zhehai Wang
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
| | - Sensen Cheng
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
| | - Xuelian Li
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
- Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, People’s Republic of China
| | - Yangwu Ren
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, People’s Republic of China
- Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, People’s Republic of China
| | - Ping Cui
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
| | - Motoki Iwasaki
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan
| | - Taichi Shimazu
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan
| | - Shoichiro Tsugane
- Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan
| | - Junjie Zhu
- Shanghai Pulmonary Hospital, Shanghai, People’s Republic of China
| | - Gening Jiang
- Shanghai Pulmonary Hospital, Shanghai, People’s Republic of China
| | - Ke Fei
- Shanghai Pulmonary Hospital, Shanghai, People’s Republic of China
| | - Guoping Wu
- China National Environmental Monitoring Center, Beijing, People’s Republic of China
| | - Li-Hsin Chien
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Hui-Ling Chen
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Yu-Chun Su
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Fang-Yu Tsai
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | - Yi-Song Chen
- Institute of Population Health Sciences, National Health Research Institutes, Zhunan, Taiwan
| | - Jinming Yu
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, People’s Republic of China
| | | | - Ite A. Laird-Offringa
- Department of Surgery, Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Crystal N. Marconett
- Department of Surgery, Department of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Dongxin Lin
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
| | - Kexin Chen
- Department of Epidemiology and Biostatistics, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People’s Republic of China
| | - Yi-Long Wu
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, People’s Republic of China
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Hongbing Shen
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
- Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, People’s Republic of China
| | - Nathaniel Rothman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Takashi Kohno
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| | - Qing Lan
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
| |
Collapse
|
106
|
Amos CI, Dennis J, Wang Z, Byun J, Schumacher FR, Gayther SA, Casey G, Hunter DJ, Sellers TA, Gruber SB, Dunning AM, Michailidou K, Fachal L, Doheny K, Spurdle AB, Li Y, Xiao X, Romm J, Pugh E, Coetzee GA, Hazelett DJ, Bojesen SE, Caga-Anan C, Haiman CA, Kamal A, Luccarini C, Tessier D, Vincent D, Bacot F, Van Den Berg DJ, Nelson S, Demetriades S, Goldgar DE, Couch FJ, Forman JL, Giles GG, Conti DV, Bickeböller H, Risch A, Waldenberger M, Brüske-Hohlfeld I, Hicks BD, Ling H, McGuffog L, Lee A, Kuchenbaecker K, Soucy P, Manz J, Cunningham JM, Butterbach K, Kote-Jarai Z, Kraft P, FitzGerald L, Lindström S, Adams M, McKay JD, Phelan CM, Benlloch S, Kelemen LE, Brennan P, Riggan M, O'Mara TA, Shen H, Shi Y, Thompson DJ, Goodman MT, Nielsen SF, Berchuck A, Laboissiere S, Schmit SL, Shelford T, Edlund CK, Taylor JA, Field JK, Park SK, Offit K, Thomassen M, Schmutzler R, Ottini L, Hung RJ, Marchini J, Amin Al Olama A, Peters U, Eeles RA, Seldin MF, Gillanders E, Seminara D, Antoniou AC, Pharoah PDP, Chenevix-Trench G, Chanock SJ, Simard J, Easton DF. The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 2017; 26:126-135. [PMID: 27697780 PMCID: PMC5224974 DOI: 10.1158/1055-9965.epi-16-0106] [Citation(s) in RCA: 245] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2016] [Revised: 06/30/2016] [Accepted: 07/29/2016] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND Common cancers develop through a multistep process often including inherited susceptibility. Collaboration among multiple institutions, and funding from multiple sources, has allowed the development of an inexpensive genotyping microarray, the OncoArray. The array includes a genome-wide backbone, comprising 230,000 SNPs tagging most common genetic variants, together with dense mapping of known susceptibility regions, rare variants from sequencing experiments, pharmacogenetic markers, and cancer-related traits. METHODS The OncoArray can be genotyped using a novel technology developed by Illumina to facilitate efficient genotyping. The consortium developed standard approaches for selecting SNPs for study, for quality control of markers, and for ancestry analysis. The array was genotyped at selected sites and with prespecified replicate samples to permit evaluation of genotyping accuracy among centers and by ethnic background. RESULTS The OncoArray consortium genotyped 447,705 samples. A total of 494,763 SNPs passed quality control steps with a sample success rate of 97% of the samples. Participating sites performed ancestry analysis using a common set of markers and a scoring algorithm based on principal components analysis. CONCLUSIONS Results from these analyses will enable researchers to identify new susceptibility loci, perform fine-mapping of new or known loci associated with either single or multiple cancers, assess the degree of overlap in cancer causation and pleiotropic effects of loci that have been identified for disease-specific risk, and jointly model genetic, environmental, and lifestyle-related exposures. IMPACT Ongoing analyses will shed light on etiology and risk assessment for many types of cancer. Cancer Epidemiol Biomarkers Prev; 26(1); 126-35. ©2016 AACR.
Collapse
Affiliation(s)
- Christopher I Amos
- Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire.
| | - Joe Dennis
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Zhaoming Wang
- Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Jinyoung Byun
- Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
| | - Fredrick R Schumacher
- Department of Epidemiology and Biostatistics, School of Medicine, Case Western Reserve University, Cleveland, Ohio
| | - Simon A Gayther
- The Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center, Greater Los Angeles Area, Los Angeles, California
| | - Graham Casey
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
| | - David J Hunter
- Department of Epidemiology, Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts
| | - Thomas A Sellers
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
| | - Stephen B Gruber
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
| | - Alison M Dunning
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Kyriaki Michailidou
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Laura Fachal
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Kimberly Doheny
- Center for Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Amanda B Spurdle
- Molecular Cancer Epidemiology, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Yafang Li
- Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
| | - Xiangjun Xiao
- Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
| | - Jane Romm
- Center for Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Elizabeth Pugh
- Center for Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | | | | | - Stig E Bojesen
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
| | - Charlisse Caga-Anan
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Christopher A Haiman
- The Center for Bioinformatics and Functional Genomics at Cedars Sinai Medical Center, Greater Los Angeles Area, Los Angeles, California
| | - Ahsan Kamal
- Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
| | - Craig Luccarini
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Daniel Tessier
- Génome Québec Innovation Centre, Montreal, Canada and McGill University, Montreal, Canada
| | - Daniel Vincent
- Génome Québec Innovation Centre, Montreal, Canada and McGill University, Montreal, Canada
| | - François Bacot
- Génome Québec Innovation Centre, Montreal, Canada and McGill University, Montreal, Canada
| | - David J Van Den Berg
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
| | - Stefanie Nelson
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Stephen Demetriades
- University Health Network- The Princess Margaret Cancer Centre, Toronto, California
| | | | | | - Judith L Forman
- Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire
| | - Graham G Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia
- Cancer, Genetics and Immunology, Menzies Institute for Medical Research, Hobart, Australia
| | - David V Conti
- Division of Biostatistics, Department of Preventive Medicine, Zilkha Neurogenetic Institute, University of Southern California, Los Angeles, California
| | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University, Göttingen, Germany
| | - Angela Risch
- University of Salzburg and Cancer Cluster Salzburg, Salzburg, Austria
- Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center, Heidelberg, Germany
- Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research, Heidelberg, Germany
| | - Melanie Waldenberger
- Research Unit of Molecular Epidemiology, Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | - Irene Brüske-Hohlfeld
- Helmholtz Zentrum München, Institut für Epidemiologie I, Neuherberg, Oberschleissheim, Germany
| | - Belynda D Hicks
- Cancer Genomics Research Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland
| | - Hua Ling
- Center for Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Lesley McGuffog
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia
- Cancer, Genetics and Immunology, Menzies Institute for Medical Research, Hobart, Australia
| | - Andrew Lee
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Karoline Kuchenbaecker
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Penny Soucy
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Canada
| | - Judith Manz
- Research Unit of Molecular Epidemiology, Institute of Epidemiology II, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | | | - Katja Butterbach
- Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany
| | | | - Peter Kraft
- Department of Epidemiology, Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts
| | - Liesel FitzGerald
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Australia
- Cancer, Genetics and Immunology, Menzies Institute for Medical Research, Hobart, Australia
| | - Sara Lindström
- Department of Epidemiology, Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, Massachusetts
- Department of Epidemiology, University of Washington, Seattle, Washington
| | - Marcia Adams
- Center for Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - James D McKay
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Catherine M Phelan
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
| | - Sara Benlloch
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Linda E Kelemen
- Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina
| | - Paul Brennan
- International Agency for Research on Cancer, World Health Organization, Lyon, France
| | - Marjorie Riggan
- Department of Gynecology, Duke University Medical Center, Durham, North Carolina
| | - Tracy A O'Mara
- Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - Hongbing Shen
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Medicine, School of Public Health, Nanjing Medical University, Nanjing, P.R. China
| | - Yongyong Shi
- Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Bio-X Institutes, Shanghai Jiao Tong University, Shanghai, P.R. China
| | - Deborah J Thompson
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | | | - Sune F Nielsen
- Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
- Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Copenhagen, Denmark
| | - Andrew Berchuck
- Department of Gynecology, Duke University Medical Center, Durham, North Carolina
| | - Sylvie Laboissiere
- Génome Québec Innovation Centre, Montreal, Canada and McGill University, Montreal, Canada
| | - Stephanie L Schmit
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
- Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida
| | - Tameka Shelford
- Center for Inherited Disease Research, Institute of Genetic Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland
| | - Christopher K Edlund
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, California
| | - Jack A Taylor
- Molecular and Genetic Epidemiology Group, National Institute for Environmental Health Sciences, Research Triangle Park, North Carolina
| | - John K Field
- Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom
| | - Sue K Park
- College of Medicine, Seoul National University, Gwanak-gu, Seoul, Korea
| | - Kenneth Offit
- Clinical Genetics Service, Memorial Hospital, New York, New York
- Cancer Biology and Genetics Program, Sloan Kettering Institute, New York, New York
- Department of Medicine, Weill Cornell Medical College, New York, New York
| | - Mads Thomassen
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
| | - Rita Schmutzler
- Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany
| | - Laura Ottini
- Department of Molecular Medicine, Sapienza, University of Rome, Rome, Italy
| | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | | | - Ali Amin Al Olama
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Ulrike Peters
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
| | | | - Michael F Seldin
- Department of Biochemistry and Molecular Medicine, University of California at Davis, Davis, California
- Department of Internal Medicine, University of California at Davis, Davis, California
| | - Elizabeth Gillanders
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Daniela Seminara
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Antonis C Antoniou
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Paul D P Pharoah
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | | | - Stephen J Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland
| | - Jacques Simard
- Cancer Genomics Laboratory, Centre Hospitalier Universitaire de Québec and Laval University, Québec City, Canada
| | - Douglas F Easton
- Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| |
Collapse
|
107
|
Shi J, Park JH, Duan J, Berndt ST, Moy W, Yu K, Song L, Wheeler W, Hua X, Silverman D, Garcia-Closas M, Hsiung CA, Figueroa JD, Cortessis VK, Malats N, Karagas MR, Vineis P, Chang IS, Lin D, Zhou B, Seow A, Matsuo K, Hong YC, Caporaso NE, Wolpin B, Jacobs E, Petersen GM, Klein AP, Li D, Risch H, Sanders AR, Hsu L, Schoen RE, Brenner H, Stolzenberg-Solomon R, Gejman P, Lan Q, Rothman N, Amundadottir LT, Landi MT, Levinson DF, Chanock SJ, Chatterjee N. Winner's Curse Correction and Variable Thresholding Improve Performance of Polygenic Risk Modeling Based on Genome-Wide Association Study Summary-Level Data. PLoS Genet 2016; 12:e1006493. [PMID: 28036406 PMCID: PMC5201242 DOI: 10.1371/journal.pgen.1006493] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2016] [Accepted: 11/16/2016] [Indexed: 12/20/2022] Open
Abstract
Recent heritability analyses have indicated that genome-wide association studies (GWAS) have the potential to improve genetic risk prediction for complex diseases based on polygenic risk score (PRS), a simple modelling technique that can be implemented using summary-level data from the discovery samples. We herein propose modifications to improve the performance of PRS. We introduce threshold-dependent winner's-curse adjustments for marginal association coefficients that are used to weight the single-nucleotide polymorphisms (SNPs) in PRS. Further, as a way to incorporate external functional/annotation knowledge that could identify subsets of SNPs highly enriched for associations, we propose variable thresholds for SNPs selection. We applied our methods to GWAS summary-level data of 14 complex diseases. Across all diseases, a simple winner's curse correction uniformly led to enhancement of performance of the models, whereas incorporation of functional SNPs was beneficial only for selected diseases. Compared to the standard PRS algorithm, the proposed methods in combination led to notable gain in efficiency (25-50% increase in the prediction R2) for 5 of 14 diseases. As an example, for GWAS of type 2 diabetes, winner's curse correction improved prediction R2 from 2.29% based on the standard PRS to 3.10% (P = 0.0017) and incorporating functional annotation data further improved R2 to 3.53% (P = 2×10-5). Our simulation studies illustrate why differential treatment of certain categories of functional SNPs, even when shown to be highly enriched for GWAS-heritability, does not lead to proportionate improvement in genetic risk-prediction because of non-uniform linkage disequilibrium structure.
Collapse
Affiliation(s)
- Jianxin Shi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- * E-mail: (JS); (NC)
| | - Ju-Hyun Park
- Department of Statistics, Dongguk University, Seoul, Korea
| | - Jubao Duan
- Center for Psychiatric Genetics, Department of Psychiatry and Behavioral Sciences, North Shore University Health System Research Institute, University of Chicago Pritzker School of Medicine, Evanston, Illinois, United States of America
| | - Sonja T. Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Winton Moy
- Dept. of Statistics, Northern Illinois University, DeKalb, Illinois, United States of America
| | - Kai Yu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Lei Song
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - William Wheeler
- Information Management Services, Inc., Rockville, Maryland, United States of America
| | - Xing Hua
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Debra Silverman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Montserrat Garcia-Closas
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Chao Agnes Hsiung
- Institute of Population Health Sciences, National Health Research Institutes, Miaoli, Taiwan
| | - Jonine D. Figueroa
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Medical School, Edinburgh, United Kingdom
| | - Victoria K. Cortessis
- Department of Preventive Medicine and Department of Obstetrics and Gynecology, USC Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
- Norris Comprehensive Cancer Center, USC Keck School of Medicine, University of Southern California, Los Angeles, California, United States of America
| | - Núria Malats
- Genetic and Molecular Epidemiology Group, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - Margaret R. Karagas
- Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire, United States of America
| | - Paolo Vineis
- Human Genetics Foundation, Turin, Italy
- MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, London, United Kingdom
| | - I-Shou Chang
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | - Dongxin Lin
- Department of Etiology & Carcinogenesis, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
- State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Baosen Zhou
- Department of Epidemiology, School of Public Health, China Medical University, Shenyang, China
| | - Adeline Seow
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore
| | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Chikusa-ku, Nagoya, Japan
| | - Yun-Chul Hong
- Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Neil E. Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Brian Wolpin
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
- Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | - Eric Jacobs
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia, United States of America
| | - Gloria M. Petersen
- Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota, United States of America
| | - Alison P. Klein
- Department of Oncology, the Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America
- Department of Epidemiology, the Bloomberg School of Public Health, Baltimore, Maryland, United States of America
| | - Donghui Li
- Department of Gastrointestinal Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America
| | - Harvey Risch
- Department of Chronic Disease Epidemiology, Yale School of Public Health, New Haven, Connecticut, United States of America
| | - Alan R. Sanders
- Center for Psychiatric Genetics, Department of Psychiatry and Behavioral Sciences, North Shore University Health System Research Institute, University of Chicago Pritzker School of Medicine, Evanston, Illinois, United States of America
| | - Li Hsu
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America
| | - Robert E. Schoen
- Department of Medicine and Epidemiology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States of America
| | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany
- German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | | | | | | | | | | | - Rachael Stolzenberg-Solomon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Pablo Gejman
- Center for Psychiatric Genetics, Department of Psychiatry and Behavioral Sciences, North Shore University Health System Research Institute, University of Chicago Pritzker School of Medicine, Evanston, Illinois, United States of America
| | - Qing Lan
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Nathaniel Rothman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Laufey T. Amundadottir
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Douglas F. Levinson
- Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, California, United States of America
| | - Stephen J. Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
| | - Nilanjan Chatterjee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
- Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America
- Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
- * E-mail: (JS); (NC)
| |
Collapse
|
108
|
Karami S, Han Y, Pande M, Cheng I, Rudd J, Pierce BL, Nutter EL, Schumacher FR, Kote-Jarai Z, Lindstrom S, Witte JS, Fang S, Han J, Kraft P, Hunter DJ, Song F, Hung RJ, McKay J, Gruber SB, Chanock SJ, Risch A, Shen H, Haiman CA, Boardman L, Ulrich CM, Casey G, Peters U, Amin Al Olama A, Berchuck A, Berndt SI, Bezieau S, Brennan P, Brenner H, Brinton L, Caporaso N, Chan AT, Chang-Claude J, Christiani DC, Cunningham JM, Easton D, Eeles RA, Eisen T, Gala M, Gallinger SJ, Gayther SA, Goode EL, Grönberg H, Henderson BE, Houlston R, Joshi AD, Küry S, Landi MT, Le Marchand L, Muir K, Newcomb PA, Permuth-Wey J, Pharoah P, Phelan C, Potter JD, Ramus SJ, Risch H, Schildkraut J, Slattery ML, Song H, Wentzensen N, White E, Wiklund F, Zanke BW, Sellers TA, Zheng W, Chatterjee N, Amos CI, Doherty JA. Telomere structure and maintenance gene variants and risk of five cancer types. Int J Cancer 2016; 139:2655-2670. [PMID: 27459707 PMCID: PMC5198774 DOI: 10.1002/ijc.30288] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/11/2016] [Accepted: 06/21/2016] [Indexed: 01/20/2023]
Abstract
Telomeres cap chromosome ends, protecting them from degradation, double-strand breaks, and end-to-end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded by TERC. Loci in the TERT and adjoining CLPTM1L region are associated with risk of multiple cancers. We therefore investigated associations between variants in 22 telomere structure and maintenance gene regions and colorectal, breast, prostate, ovarian, and lung cancer risk. We performed subset-based meta-analyses of 204,993 directly-measured and imputed SNPs among 61,851 cancer cases and 74,457 controls of European descent. Independent associations for SNP minor alleles were identified using sequential conditional analysis (with gene-level p value cutoffs ≤3.08 × 10-5 ). Of the thirteen independent SNPs observed to be associated with cancer risk, novel findings were observed for seven loci. Across the DCLRE1B region, rs974494 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Across the TERC region, rs75316749 was positively associated with colorectal, breast, ovarian, and lung cancers. Across the DCLRE1B region, rs974404 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Near POT1, rs116895242 was inversely associated with colorectal, ovarian, and lung cancers, and RTEL1 rs34978822 was inversely associated with prostate and lung cancers. The complex association patterns in telomere-related genes across cancer types may provide insight into mechanisms through which telomere dysfunction in different tissues influences cancer risk.
Collapse
Affiliation(s)
- Sara Karami
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
| | - Younghun Han
- The Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH
| | - Mala Pande
- Department of Gastroenterology, Hepatology and Nutrition, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Iona Cheng
- Cancer Prevention Institute of California, Fremont, CA; Stanford Cancer Institute, Stanford, CA
| | - James Rudd
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
| | - Brandon L Pierce
- Departments of Public Health Sciences and Human Genetics and Comprehensive Cancer Center, The University of Chicago, Chicago, IL
| | - Ellen L Nutter
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH
| | - Fredrick R Schumacher
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Zsofia Kote-Jarai
- Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Sara Lindstrom
- Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. School of Public Health, Boston, MA
| | - John S Witte
- Division of Genetic and Cancer Epidemiology, Department of Epidemiology and Biostatistics and Institute of Human Genetics, University of California, San Francisco, CA
| | - Shenying Fang
- Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Jiali Han
- Department of Epidemiology, Fairbanks School of Public Health, Simon Cancer Center, Indiana University, Indianapolis, IN
| | - Peter Kraft
- Department of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA
| | - David J Hunter
- Department of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA
| | - Fengju Song
- Department of Epidemiology and Biostatistics, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Centre of Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, People's Republic of China
| | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - James McKay
- Genetic Cancer Susceptibility Group, Genetic Epidemiology Group International Agency for Research on Cancer (IARC), Lyon, France
| | - Stephen B Gruber
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Stephen J Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Angela Risch
- Division of Epigenomics and Cancer Risk Factors, German Cancer Research Center (DKFZ), Heidelberg, Germany; Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - Hongbing Shen
- Department of Epidemiology and Biostatistics, Collaborative Innovation Center for Cancer Medicine, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, School of Public Health, Nanjing Medical University, Nanjing, People's Republic of China
| | - Christopher A Haiman
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | | | - Cornelia M Ulrich
- Huntsman Cancer Institute, Salt Lake City, UT
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Graham Casey
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | - Ulrike Peters
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Ali Amin Al Olama
- Department of Public Health and Primary Care, Center for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
| | - Andrew Berchuck
- Department of Obstetrics and Gynecology, Duke University, Durham, NC
| | - Sonja I Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | | | - Paul Brennan
- Genetic Cancer Susceptibility Group, Genetic Epidemiology Group International Agency for Research on Cancer (IARC), Lyon, France
| | - Hermann Brenner
- Klinische Epidemiologie und Alternsforschung, Deutsches Krebsforschungszentrum, Heidelberg, Germany
| | - Louise Brinton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Andrew T Chan
- Division of Gastroenterology, Massachusetts General Hospital, Boston, MA
- Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - David C Christiani
- Program in Genetic Epidemiology and Statistical Genetics, Harvard T.H. School of Public Health, Boston, MA
| | | | - Douglas Easton
- Department of Public Health and Primary Care, Center for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, United Kingdom
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom
| | - Rosalind A Eeles
- Oncogenetics Team, The Institute of Cancer Research and Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Timothy Eisen
- Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, United Kingdom
| | - Manish Gala
- Division of Gastroenterology, Massachusetts General Hospital, Boston, MA
| | - Steven J Gallinger
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada
| | - Simon A Gayther
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | | | - Henrik Grönberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Brian E Henderson
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | | | - Amit D Joshi
- Department of Epidemiology and Biostatistics, Harvard School of Public Health, Boston, MA
| | - Sébastien Küry
- Service de Génétique Médicale, CHU Nantes, Nantes, France
| | - Mari T Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Loic Le Marchand
- Division of Epidemiology, University of Hawaii Cancer Center, Honolulu, HI
| | - Kenneth Muir
- Warwick Medical School, University of Warwick, Coventry, United Kingdom
- Institute of Population Health, University of Manchester, Manchester, United Kingdom
| | - Polly A Newcomb
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | | | - Paul Pharoah
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom
| | | | - John D Potter
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Susan J Ramus
- Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA
| | | | | | | | - Honglin Song
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom
| | - Nicolas Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Emily White
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Brent W Zanke
- Division of Hematology, The University of Ottawa, Ottawa Hospital Research Institute, Ottawa, ON
| | | | - Wei Zheng
- Vanderbilt Epidemiology Center and Division of Epidemiology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN
| | - Nilanjan Chatterjee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Christopher I Amos
- The Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Lebanon, NH
| | - Jennifer A Doherty
- Department of Epidemiology, Geisel School of Medicine at Dartmouth, Lebanon, NH.
| |
Collapse
|
109
|
Lesseur C, Diergaarde B, Olshan AF, Wünsch-Filho V, Ness AR, Liu G, Lacko M, Eluf-Neto J, Franceschi S, Lagiou P, Macfarlane GJ, Richiardi L, Boccia S, Polesel J, Kjaerheim K, Zaridze D, Johansson M, Menezes AM, Curado MP, Robinson M, Ahrens W, Canova C, Znaor A, Castellsagué X, Conway DI, Holcátová I, Mates D, Vilensky M, Healy CM, Szeszenia-Dąbrowska N, Fabiánová E, Lissowska J, Grandis JR, Weissler MC, Tajara EH, Nunes FD, de Carvalho MB, Thomas S, Hung RJ, Peters WHM, Herrero R, Cadoni G, Bueno-de-Mesquita HB, Steffen A, Agudo A, Shangina O, Xiao X, Gaborieau V, Chabrier A, Anantharaman D, Boffetta P, Amos CI, McKay JD, Brennan P. Genome-wide association analyses identify new susceptibility loci for oral cavity and pharyngeal cancer. Nat Genet 2016; 48:1544-1550. [PMID: 27749845 PMCID: PMC5131845 DOI: 10.1038/ng.3685] [Citation(s) in RCA: 139] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Accepted: 09/01/2016] [Indexed: 02/07/2023]
Abstract
We conducted a genome-wide association study of oral cavity and pharyngeal cancer in 6,034 cases and 6,585 controls from Europe, North America and South America. We detected eight significantly associated loci (P < 5 × 10-8), seven of which are new for these cancer sites. Oral and pharyngeal cancers combined were associated with loci at 6p21.32 (rs3828805, HLA-DQB1), 10q26.13 (rs201982221, LHPP) and 11p15.4 (rs1453414, OR52N2-TRIM5). Oral cancer was associated with two new regions, 2p23.3 (rs6547741, GPN1) and 9q34.12 (rs928674, LAMC3), and with known cancer-related loci-9p21.3 (rs8181047, CDKN2B-AS1) and 5p15.33 (rs10462706, CLPTM1L). Oropharyngeal cancer associations were limited to the human leukocyte antigen (HLA) region, and classical HLA allele imputation showed a protective association with the class II haplotype HLA-DRB1*1301-HLA-DQA1*0103-HLA-DQB1*0603 (odds ratio (OR) = 0.59, P = 2.7 × 10-9). Stratified analyses on a subgroup of oropharyngeal cases with information available on human papillomavirus (HPV) status indicated that this association was considerably stronger in HPV-positive (OR = 0.23, P = 1.6 × 10-6) than in HPV-negative (OR = 0.75, P = 0.16) cancers.
Collapse
Affiliation(s)
- Corina Lesseur
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | - Brenda Diergaarde
- Department of Epidemiology, Graduate School of Public Health,
University of Pittsburgh, Pittsburgh, PA, USA
- University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA
| | - Andrew F Olshan
- Department of Epidemiology, Gillings School of Global Public Health,
University of North Carolina, NC, USA
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC,
USA
| | - Victor Wünsch-Filho
- Faculdade de Saúde Pública, Universidade de São
Paulo, São Paulo, SP, Brazil
| | - Andrew R Ness
- National Institute for Health Research (NIHR) Biomedical Research Unit in Nutrition, Diet and Lifestyle at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol , Bristol, UK
- University of Bristol and School of Oral and Dental Sciences,
University of Bristol, Bristol, UK
| | - Geoffrey Liu
- Princess Margaret Cancer Centre, Toronto, Ontario, Canada
| | - Martin Lacko
- Department of Otorhinolaryngology, Head and Neck Surgery,
Maastricht University Medical Center, Maastricht, Netherlands
| | - José Eluf-Neto
- Departamento de Medicina Preventiva, Faculdade de Medicina da
Universidade de São Paulo, São Paulo, Brazil
| | - Silvia Franceschi
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | - Pagona Lagiou
- Department of Hygiene, Epidemiology and Medical Statistics, School
of Medicine, National Kapodistrian University of Athens, Athens, Greece
| | - Gary J Macfarlane
- School of Medicine, Medical Sciences and Nutrition, University of
Aberdeen, Aberdeen, UK
| | | | - Stefania Boccia
- Section of Hygiene, Institute of Public Health, Università
Cattolica del Sacro Cuore, Fondazione Policlinico ‘Agostino Gemelli’,
Rome, Italy
| | - Jerry Polesel
- Unit of Cancer Epidemiology, CRO Aviano National Cancer Institute,
Aviano, Italy
| | | | - David Zaridze
- Department of Cancer Epidemiology and Prevention, Institute of
Carcinogenesis, N.N. Blokhin Russian Cancer Research Centre of the Russian Ministry
of Health, Moscow, Russian Federation
| | - Mattias Johansson
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | - Ana M Menezes
- Programa de Pós-Graduacão em Epidemiologia, Universidade Federal de Pelotas (UFPel), Pelotas, Brazil
| | - Maria Paula Curado
- Epidemiology, International Center for Research (CIPE), A.C.Camargo
Cancer Center, Sao Paulo, Brazil
| | - Max Robinson
- Centre for Oral Health Research, Newcastle University, Newcastle,
UK
| | - Wolfgang Ahrens
- Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany
| | - Cristina Canova
- Deparment of Molecular Medicine, University of Padova, Padova,
Italy
| | - Ariana Znaor
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
- Croatian National Institute of Public Health, Zagreb, Croatia
| | - Xavier Castellsagué
- Institut Català d’Oncologia (ICO)-DIBELL, CIBER-ESP,
L’Hospitalet de Llobregat, Catalonia, Spain
| | - David I Conway
- School of Medicine, Dentistry and Nursing, University of Glasgow, University of Glasgow, Glasgow, UK
- NHS NSS National Services Scotland, Edinburgh, UK
| | - Ivana Holcátová
- Institute of Hygiene & Epidemiology 1st Faculty of Medicine,
Charles University, Prague, Czech Republic
| | - Dana Mates
- National Institute of Public Health, Bucharest, Romania
| | - Marta Vilensky
- Instituto de Oncologia “Angel H Roffo“, Universidad
de Buenos Aires, Buenos Aires, Argentina
| | - Claire M Healy
- Trinity College School of Dental Science, Dublin, Ireland
| | | | | | - Jolanta Lissowska
- The Maria Skłodowska-Curie Memorial Cancer Centre and
Institute of Oncology (MCMCC), Warsaw, Poland
| | - Jennifer R Grandis
- Department of Otolaryngology-Head and Neck Surgery, University of California San Francisco, San Francisco, California, USA
- Clinical Translational Science Institute, University of California
at San Francisco, San Francisco, CA, USA
| | - Mark C Weissler
- Department of Otolaryngology/Head and Neck Surgery, University of
North Carolina at Chapel Hill, Chapel Hill, NC, USA
| | - Eloiza H Tajara
- Department of Molecular Biology, School of Medicine of São
José do Rio Preto, São José do Rio Preto, SP, Brazil
| | - Fabio D Nunes
- Department of Stomatology, School of Dentistry, University of
São Paulo, São Paulo, SP, Brazil
| | | | - Steve Thomas
- University of Bristol and School of Oral and Dental Sciences,
University of Bristol, Bristol, UK
| | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Wilbert H M Peters
- Department of Gastroenterology, Radboud University Nijmegen, Medical Center, Nijmegen, the Netherlands
| | - Rolando Herrero
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | - Gabriella Cadoni
- Department for Determinants of Chronic Diseases (DCD), National
Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
| | - H Bas Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National
Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK
- Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Annika Steffen
- German Institute of Human Nutrition in Potsdam-Rehbruecke (DIfE), Nuthetal, Germany
| | - Antonio Agudo
- Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Català d’Oncologia (ICO)-IDIBELL, l’Hospitalet de Llobregat, Barcelona, Spain
| | - Oxana Shangina
- Department of Cancer Epidemiology and Prevention, Institute of
Carcinogenesis, N.N. Blokhin Russian Cancer Research Centre of the Russian Ministry
of Health, Moscow, Russian Federation
| | - Xiangjun Xiao
- Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA
| | - Valérie Gaborieau
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | - Amélie Chabrier
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | | | - Paolo Boffetta
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA
| | - Christopher I Amos
- Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire, USA
| | - James D McKay
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| | - Paul Brennan
- International Agency for Research on Cancer (IARC/WHO), Lyon,
France
| |
Collapse
|
110
|
Hjelmborg J, Korhonen T, Holst K, Skytthe A, Pukkala E, Kutschke J, Harris JR, Mucci LA, Christensen K, Czene K, Adami HO, Scheike T, Kaprio J. Lung cancer, genetic predisposition and smoking: the Nordic Twin Study of Cancer. Thorax 2016; 72:1021-1027. [DOI: 10.1136/thoraxjnl-2015-207921] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2015] [Revised: 10/02/2016] [Accepted: 10/04/2016] [Indexed: 01/07/2023]
|
111
|
Yuan H, Liu H, Liu Z, Owzar K, Han Y, Su L, Wei Y, Hung RJ, McLaughlin J, Brhane Y, Brennan P, Bickeboeller H, Rosenberger A, Houlston RS, Caporaso N, Landi MT, Heinrich J, Risch A, Christiani DC, Gümüş ZH, Klein RJ, Amos CI, Wei Q. A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. Sci Rep 2016; 6:34234. [PMID: 27713484 PMCID: PMC5054367 DOI: 10.1038/srep34234] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 09/06/2016] [Indexed: 12/27/2022] Open
Abstract
Lung cancer etiology is multifactorial, and growing evidence has indicated that long non-coding RNAs (lncRNAs) are important players in lung carcinogenesis. We performed a large-scale meta-analysis of 690,564 SNPs in 15,531 autosomal lncRNAs by using datasets from six previously published genome-wide association studies (GWASs) from the Transdisciplinary Research in Cancer of the Lung (TRICL) consortium in populations of European ancestry. Previously unreported significant SNPs (P value < 1 × 10-7) were further validated in two additional independent lung cancer GWAS datasets from Harvard University and deCODE. In the final meta-analysis of all eight GWAS datasets with 17,153 cases and 239,337 controls, a novel risk SNP rs114020893 in the lncRNA NEXN-AS1 region at 1p31.1 remained statistically significant (odds ratio = 1.17; 95% confidence interval = 1.11-1.24; P = 8.31 × 10-9). In further in silico analysis, rs114020893 was predicted to change the secondary structure of the lncRNA. Our finding indicates that SNP rs114020893 of NEXN-AS1 at 1p31.1 may contribute to lung cancer susceptibility.
Collapse
Affiliation(s)
- Hua Yuan
- Collaborative Innovation Center For Cancer Personalized Medicine, Nanjing Medical University; Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Stomatology, Nanjing Medical University, Nanjing, China
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA
- Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| | - Hongliang Liu
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA
- Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| | - Zhensheng Liu
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA
- Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| | - Kouros Owzar
- Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC, USA
| | - Younghun Han
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NC, USA
| | - Li Su
- Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Yongyue Wei
- Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
| | | | - Yonathan Brhane
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), Lyon, France
| | - Heike Bickeboeller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Albert Rosenberger
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Richard S. Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
| | - Neil Caporaso
- Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Maria Teresa Landi
- Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
| | - Joachim Heinrich
- Helmholtz Centre Munich, German Research Centre for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
- Institute and Outpatient Clinic for Occupational, Social and Environmental Medicine, University Hospital Munich, Ludwig Maximilian University Munich, Munich, Germany
| | - Angela Risch
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
- Department of Epigenomics and Cancer Risk Factors, DKFZ-German Cancer Research Center, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - David C. Christiani
- Massachusetts General Hospital, Boston, Massachusetts, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts, USA
| | - Zeynep H. Gümüş
- Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Robert J. Klein
- Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, USA
| | - Christopher I. Amos
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NC, USA
| | - Qingyi Wei
- Department of Medicine, Duke University School of Medicine, Durham, NC, USA
- Duke Cancer Institute, Duke University Medical Center, Durham, NC, USA
| |
Collapse
|
112
|
Patel YM, Park SL, Han Y, Wilkens LR, Bickeböller H, Rosenberger A, Caporaso N, Landi MT, Brüske I, Risch A, Wei Y, Christiani DC, Brennan P, Houlston R, McKay J, McLaughlin J, Hung R, Murphy S, Stram DO, Amos C, Le Marchand L. Novel Association of Genetic Markers Affecting CYP2A6 Activity and Lung Cancer Risk. Cancer Res 2016; 76:5768-5776. [PMID: 27488534 PMCID: PMC5050097 DOI: 10.1158/0008-5472.can-16-0446] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2016] [Accepted: 06/10/2016] [Indexed: 01/28/2023]
Abstract
Metabolism of nicotine by cytochrome P450 2A6 (CYP2A6) is a suspected determinant of smoking dose and, consequently, lung cancer risk. We conducted a genome-wide association study (GWAS) of CYP2A6 activity, as measured by the urinary ratio of trans-3'-hydroxycotinine and its glucuronide conjugate over cotinine (total 3HCOT/COT), among 2,239 smokers in the Multiethnic Cohort (MEC) study. We identified 248 CYP2A6 variants associated with CYP2A6 activity (P < 5 × 10-8). CYP2A6 activity was correlated (r = 0.32; P < 0.0001) with total nicotine equivalents (a measure of nicotine uptake). When we examined the effect of these variants on lung cancer risk in the Transdisciplinary Research in Cancer of the Lung (TRICL) consortium GWAS dataset (13,479 cases and 43,218 controls), we found that the vast majority of these individual effects were directionally consistent and associated with an increased lung cancer risk. Two hundred and twenty-six of the 248 variants associated with CYP2A6 activity in the MEC were available in TRICL. Of them, 81% had directionally consistent risk estimates, and six were globally significantly associated with lung cancer. When conditioning on nine known functional variants and two deletions, the top two SNPs (rs56113850 in MEC and rs35755165 in TRICL) remained significantly associated with CYP2A6 activity in MEC and lung cancer in TRICL. The present data support the hypothesis that a greater CYP2A6 activity causes smokers to smoke more extensively and be exposed to higher levels of carcinogens, resulting in an increased risk for lung cancer. Although the variants identified in these studies may be used as risk prediction markers, the exact causal variants remain to be identified. Cancer Res; 76(19); 5768-76. ©2016 AACR.
Collapse
Affiliation(s)
- Yesha M Patel
- Department of Preventive Medicine and Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Sunghim L Park
- Department of Preventive Medicine and Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Younghun Han
- Department of Biomedical Data Science, Dartmouth College, Hanover, New Hampshire
| | - Lynne R Wilkens
- Epidemiology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii
| | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Albert Rosenberger
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, Maryland
| | - Irene Brüske
- Helmholtz Centre Munich, German Research Centre for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
| | - Angela Risch
- Department of Molecular Biology, University of Salzburg, Salzburg, Austria
| | - Yongyue Wei
- Nanjing Medical University School of Public Health, Nanjing, China
| | - David C Christiani
- Massachusetts General Hospital, Boston, Massachusetts. Department of Environmental Health, Harvard School of Public Health, Boston, Massachusetts
| | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), Lyon, France
| | - Richard Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom
| | - James McKay
- Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), Lyon, France
| | | | - Rayjean Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Sharon Murphy
- Department of Biochemistry Molecular Biology and Biophysics and Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
| | - Daniel O Stram
- Department of Preventive Medicine and Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California
| | - Christopher Amos
- Department of Biomedical Data Science, Dartmouth College, Hanover, New Hampshire
| | - Loïc Le Marchand
- Epidemiology Program, University of Hawai'i Cancer Center, Honolulu, Hawaii.
| |
Collapse
|
113
|
Fehringer G, Kraft P, Pharoah PD, Eeles RA, Chatterjee N, Schumacher FR, Schildkraut JM, Lindström S, Brennan P, Bickeböller H, Houlston RS, Landi MT, Caporaso N, Risch A, Amin Al Olama A, Berndt SI, Giovannucci EL, Grönberg H, Kote-Jarai Z, Ma J, Muir K, Stampfer MJ, Stevens VL, Wiklund F, Willett WC, Goode EL, Permuth JB, Risch HA, Reid BM, Bezieau S, Brenner H, Chan AT, Chang-Claude J, Hudson TJ, Kocarnik JK, Newcomb PA, Schoen RE, Slattery ML, White E, Adank MA, Ahsan H, Aittomäki K, Baglietto L, Blomquist C, Canzian F, Czene K, Dos-Santos-Silva I, Eliassen AH, Figueroa JD, Flesch-Janys D, Fletcher O, Garcia-Closas M, Gaudet MM, Johnson N, Hall P, Hazra A, Hein R, Hofman A, Hopper JL, Irwanto A, Johansson M, Kaaks R, Kibriya MG, Lichtner P, Liu J, Lund E, Makalic E, Meindl A, Müller-Myhsok B, Muranen TA, Nevanlinna H, Peeters PH, Peto J, Prentice RL, Rahman N, Sanchez MJ, Schmidt DF, Schmutzler RK, Southey MC, Tamimi R, Travis RC, Turnbull C, Uitterlinden AG, Wang Z, Whittemore AS, Yang XR, Zheng W, Buchanan DD, Casey G, Conti DV, Edlund CK, Gallinger S, Haile RW, Jenkins M, Le Marchand L, Li L, Lindor NM, Schmit SL, Thibodeau SN, Woods MO, Rafnar T, Gudmundsson J, Stacey SN, Stefansson K, Sulem P, Chen YA, Tyrer JP, Christiani DC, Wei Y, Shen H, Hu Z, Shu XO, Shiraishi K, Takahashi A, Bossé Y, Obeidat M, Nickle D, Timens W, Freedman ML, Li Q, Seminara D, Chanock SJ, Gong J, Peters U, Gruber SB, Amos CI, Sellers TA, Easton DF, Hunter DJ, Haiman CA, Henderson BE, Hung RJ. Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. Cancer Res 2016; 76:5103-14. [PMID: 27197191 PMCID: PMC5010493 DOI: 10.1158/0008-5472.can-15-2980] [Citation(s) in RCA: 77] [Impact Index Per Article: 9.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2015] [Accepted: 04/05/2016] [Indexed: 01/26/2023]
Abstract
Identifying genetic variants with pleiotropic associations can uncover common pathways influencing multiple cancers. We took a two-stage approach to conduct genome-wide association studies for lung, ovary, breast, prostate, and colorectal cancer from the GAME-ON/GECCO Network (61,851 cases, 61,820 controls) to identify pleiotropic loci. Findings were replicated in independent association studies (55,789 cases, 330,490 controls). We identified a novel pleiotropic association at 1q22 involving breast and lung squamous cell carcinoma, with eQTL analysis showing an association with ADAM15/THBS3 gene expression in lung. We also identified a known breast cancer locus CASP8/ALS2CR12 associated with prostate cancer, a known cancer locus at CDKN2B-AS1 with different variants associated with lung adenocarcinoma and prostate cancer, and confirmed the associations of a breast BRCA2 locus with lung and serous ovarian cancer. This is the largest study to date examining pleiotropy across multiple cancer-associated loci, identifying common mechanisms of cancer development and progression. Cancer Res; 76(17); 5103-14. ©2016 AACR.
Collapse
Affiliation(s)
- Gordon Fehringer
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada
| | - Peter Kraft
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | | | | | | | | | | | - Sara Lindström
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Paul Brennan
- International Agency for Research on Cancer, Lyon, France
| | | | | | | | | | - Angela Risch
- Division of Cancer Genetics/Epigenetics, Department of Molecular Biology, University of Salzburg, Salzburg, Austria. Division of Epigenomics and Cancer Risk Factors, DKFZ - German Cancer Research Center, Heidelberg, Germany. Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), Heidelberg, Germany
| | | | | | | | | | | | - Jing Ma
- Harvard Medical School, Boston Massachusetts. Brigham and Women's Hospital, Boston, Massachusetts
| | - Kenneth Muir
- University of Manchester, Manchester, United Kingdom. The University of Warwick, Coventry, United Kingdom
| | | | - Victoria L Stevens
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia
| | | | - Walter C Willett
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | | | | | | | | | | | - Hermann Brenner
- Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. Division of Preventive Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Andrew T Chan
- Massachusetts General Hospital, Boston, Massachusetts
| | - Jenny Chang-Claude
- National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | | | | | - Robert E Schoen
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania
| | | | - Emily White
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Muriel A Adank
- VU University Medical Center, Amsterdam, the Netherlands
| | | | - Kristiina Aittomäki
- University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | | | - Carl Blomquist
- University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Federico Canzian
- Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Isabel Dos-Santos-Silva
- Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - A Heather Eliassen
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts. Harvard Medical School, Boston Massachusetts
| | | | | | - Olivia Fletcher
- Breakthrough Research Centre, The Institute of Cancer Research, London, United Kingdom
| | | | - Mia M Gaudet
- Epidemiology Research Program, American Cancer Society, Atlanta, Georgia
| | - Nichola Johnson
- Breakthrough Research Centre, The Institute of Cancer Research, London, United Kingdom
| | - Per Hall
- Karolinska Institutet, Stockholm, Sweden
| | - Aditi Hazra
- Harvard Medical School, Boston Massachusetts
| | - Rebecca Hein
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ) Heidelberg, Germany. Institute of Medical Statistics, Informatics and Epidemiology, University of Cologne, Cologne, Germany
| | - Albert Hofman
- Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands
| | - John L Hopper
- Melbourne School of Population Health, University of Melbourne, Melbourne, Victoria, Australia
| | | | - Mattias Johansson
- International Agency for Research on Cancer, Lyon, France. Department of Biobank Research, Umea University, Umea, Sweden
| | - Rudolf Kaaks
- National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | | | - Peter Lichtner
- German Research Center for Environmental Health, Neuherberg, Germany
| | | | - Eiliv Lund
- Institute of Community Medicine, UiT The Arctic University of Norway, Tromso, Norway
| | - Enes Makalic
- Melbourne School of Population Health, University of Melbourne, Melbourne, Victoria, Australia
| | | | | | - Taru A Muranen
- University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Heli Nevanlinna
- University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland
| | - Petra H Peeters
- Department of Epidemiology, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, the Netherlands
| | - Julian Peto
- Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | | | | | - Maria Jose Sanchez
- Escuela Andaluza de Salud Publica, Instituto de Investigacion Biosanitaria ibs. GRANADA, Granada, Spain. Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain. CIBER de Epidemiología y Salud Pública CIBERESP, Madrid, Spain
| | - Daniel F Schmidt
- Melbourne School of Population Health, University of Melbourne, Melbourne, Victoria, Australia
| | | | | | | | - Ruth C Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom
| | | | - Andre G Uitterlinden
- Department of Epidemiology, Erasmus Medical Center, Rotterdam, the Netherlands. Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands
| | | | | | | | - Wei Zheng
- Vanderbilt University, Nashville, Tennessee
| | | | - Graham Casey
- University of Southern California, Los Angeles, California
| | - David V Conti
- University of Southern California, Los Angeles, California
| | | | - Steven Gallinger
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada
| | | | - Mark Jenkins
- The University of Melbourne, Melbourne, Victoria, Australia
| | - Loïc Le Marchand
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii
| | - Li Li
- Case Comprehensive Cancer Center and Mary Ann Swetland Center for Environmental Health, Case Western Reserve University, Cleveland, Ohio
| | | | | | | | - Michael O Woods
- Memorial University of Newfoundland, St. John's, Newfoundland, Canada
| | | | | | | | | | | | | | | | | | - Yongyue Wei
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | - Hongbing Shen
- Nanjing Medical University School of Public Health, Nanjing, China
| | - Zhibin Hu
- Nanjing Medical University School of Public Health, Nanjing, China
| | | | - Kouya Shiraishi
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan
| | - Atsushi Takahashi
- Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yohan Bossé
- Department of Molecular Medicine, Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Québec, Canada
| | - Ma'en Obeidat
- University of British Columbia Centre for Heart Lung Innovation, St. Paul's Hospital, Vancouver, Canada
| | - David Nickle
- Merck & Co, Merck Research Laboratories, Seattle, Washington
| | - Wim Timens
- University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, the Netherlands
| | | | | | | | | | - Jian Gong
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Ulrike Peters
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | | | | | | | | | - David J Hunter
- Harvard T.H. Chan School of Public Health, Boston, Massachusetts
| | | | | | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada.
| |
Collapse
|
114
|
Wang M, Liu H, Liu Z, Yi X, Bickeboller H, Hung RJ, Brennan P, Landi MT, Caporaso N, Christiani DC, Doherty JA, Amos CI, Wei Q. Genetic variant in DNA repair gene GTF2H4 is associated with lung cancer risk: a large-scale analysis of six published GWAS datasets in the TRICL consortium. Carcinogenesis 2016; 37:888-896. [PMID: 27288692 PMCID: PMC5008248 DOI: 10.1093/carcin/bgw070] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 05/27/2016] [Accepted: 06/07/2016] [Indexed: 12/15/2022] Open
Abstract
DNA repair pathways maintain genomic integrity and stability, and dysfunction of DNA repair leads to cancer. We hypothesize that functional genetic variants in DNA repair genes are associated with risk of lung cancer. We performed a large-scale meta-analysis of 123,371 single nucleotide polymorphisms (SNPs) in 169 DNA repair genes obtained from six previously published genome-wide association studies (GWASs) of 12160 lung cancer cases and 16838 controls. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) using the logistic regression model and used the false discovery rate (FDR) method for correction of multiple testing. As a result, 14 SNPs had a significant odds ratio (OR) for lung cancer risk with P FDR < 0.05, of which rs3115672 in MSH5 (OR = 1.20, 95% CI = 1.14-1.27) and rs114596632 in GTF2H4 (OR = 1.19, 95% CI = 1.12-1.25) at 6q21.33 were the most statistically significant (P combined = 3.99×10(-11) and P combined = 5.40×10(-10), respectively). The MSH5 rs3115672, but not GTF2H4 rs114596632, was strongly correlated with MSH5 rs3131379 in that region (r (2) = 1.000 and r (2) = 0.539, respectively) as reported in a previous GWAS. Importantly, however, the GTF2H4 rs114596632 T, but not MSH5 rs3115672 T, allele was significantly associated with both decreased DNA repair capacity phenotype and decreased mRNA expression levels. These provided evidence that functional genetic variants of GTF2H4 confer susceptibility to lung cancer.
Collapse
Affiliation(s)
- Meilin Wang
- Duke Cancer Institute, Duke University Medical Center, 905 Lasalle Street, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 21116, China
| | - Hongliang Liu
- Duke Cancer Institute, Duke University Medical Center, 905 Lasalle Street, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Zhensheng Liu
- Duke Cancer Institute, Duke University Medical Center, 905 Lasalle Street, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Xiaohua Yi
- Duke Cancer Institute, Duke University Medical Center, 905 Lasalle Street, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Heike Bickeboller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
| | - Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai hospital, Toronto, Ontario, Canada
| | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer, 69372 Lyon, France
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
| | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
| | - David C. Christiani
- Department of Environmental Health and
- Department of Epidemiology, Harvard University School of Public Health, Boston, MA 02115, USA and
| | - Jennifer Anne Doherty
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 03756, USA
| | - The TRICL Research Team
- Duke Cancer Institute, Duke University Medical Center, 905 Lasalle Street, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
- Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing 21116, China
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai hospital, Toronto, Ontario, Canada
- Genetic Epidemiology Group, International Agency for Research on Cancer, 69372 Lyon, France
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20892, USA
- Department of Environmental Health and
- Department of Epidemiology, Harvard University School of Public Health, Boston, MA 02115, USA and
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 03756, USA
| | - Christopher I. Amos
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 03756, USA
| | - Qingyi Wei
- Duke Cancer Institute, Duke University Medical Center, 905 Lasalle Street, Durham, NC 27710, USA
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| |
Collapse
|
115
|
Malhotra J, Malvezzi M, Negri E, La Vecchia C, Boffetta P. Risk factors for lung cancer worldwide. Eur Respir J 2016; 48:889-902. [PMID: 27174888 DOI: 10.1183/13993003.00359-2016] [Citation(s) in RCA: 474] [Impact Index Per Article: 59.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Accepted: 04/04/2016] [Indexed: 02/06/2023]
Abstract
Lung cancer is the most frequent malignant neoplasm in most countries, and the main cancer-related cause of mortality worldwide in both sexes combined.The geographic and temporal patterns of lung cancer incidence, as well as lung cancer mortality, on a population level are chiefly determined by tobacco consumption, the main aetiological factor in lung carcinogenesis.Other factors such as genetic susceptibility, poor diet, occupational exposures and air pollution may act independently or in concert with tobacco smoking in shaping the descriptive epidemiology of lung cancer. Moreover, novel approaches in the classification of lung cancer based on molecular techniques have started to bring new insights to its aetiology, in particular among nonsmokers. Despite the success in delineation of tobacco smoking as the major risk factor for lung cancer, this highly preventable disease remains among the most common and most lethal cancers globally.Future preventive efforts and research need to focus on non-cigarette tobacco smoking products, as well as better understanding of risk factors underlying lung carcinogenesis in never-smokers.
Collapse
Affiliation(s)
- Jyoti Malhotra
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA Rutgers Cancer Institute of New Jersey, Robert Wood Johnson Medical School, New Brunswick, NJ, USA
| | - Matteo Malvezzi
- Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy Dept of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - Eva Negri
- Dept of Epidemiology, IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy
| | - Carlo La Vecchia
- Dept of Clinical Sciences and Community Health, University of Milan, Milan, Italy
| | - Paolo Boffetta
- Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
116
|
Pradel LP, Ooi CH, Romagnoli S, Cannarile MA, Sade H, Rüttinger D, Ries CH. Macrophage Susceptibility to Emactuzumab (RG7155) Treatment. Mol Cancer Ther 2016; 15:3077-3086. [DOI: 10.1158/1535-7163.mct-16-0157] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2016] [Revised: 08/12/2016] [Accepted: 08/18/2016] [Indexed: 11/16/2022]
|
117
|
Genetic Risk Can Be Decreased: Quitting Smoking Decreases and Delays Lung Cancer for Smokers With High and Low CHRNA5 Risk Genotypes - A Meta-Analysis. EBioMedicine 2016; 11:219-226. [PMID: 27543155 PMCID: PMC5049934 DOI: 10.1016/j.ebiom.2016.08.012] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2016] [Revised: 08/05/2016] [Accepted: 08/06/2016] [Indexed: 12/02/2022] Open
Abstract
Background Recent meta-analyses show that individuals with high risk variants in CHRNA5 on chromosome 15q25 are likely to develop lung cancer earlier than those with low-risk genotypes. The same high-risk genetic variants also predict nicotine dependence and delayed smoking cessation. It is unclear whether smoking cessation confers the same benefits in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants versus those who do not. Methods Meta-analyses examined the association between smoking cessation and lung cancer risk in 15 studies of individuals with European ancestry who possessed varying rs16969968 genotypes (N = 12,690 ever smokers, including 6988 cases of lung cancer and 5702 controls) in the International Lung Cancer Consortium. Results Smoking cessation (former vs. current smokers) was associated with a lower likelihood of lung cancer (OR = 0.48, 95%CI = 0.30–0.75, p = 0.0015). Among lung cancer patients, smoking cessation was associated with a 7-year delay in median age of lung cancer diagnosis (HR = 0.68, 95%CI = 0.61–0.77, p = 4.9 ∗ 10–10). The CHRNA5 rs16969968 risk genotype (AA) was associated with increased risk and earlier diagnosis for lung cancer, but the beneficial effects of smoking cessation were very similar in those with and without the risk genotype. Conclusion We demonstrate that quitting smoking is highly beneficial in reducing lung cancer risks for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Smokers with high-risk CHRNA5 genotypes, on average, can largely eliminate their elevated genetic risk for lung cancer by quitting smoking- cutting their risk of lung cancer in half and delaying its onset by 7 years for those who develop it. These results: 1) underscore the potential value of smoking cessation for all smokers, 2) suggest that CHRNA5 rs16969968 genotype affects lung cancer diagnosis through its effects on smoking, and 3) have potential value for framing preventive interventions for those who smoke. CHRNA5 rs16969968 confers risk for earlier lung cancer diagnosis, but quitting produces benefit regardless of genotype. Smokers can cut their risk of lung cancer in half and delay its onset by 7 years among those diagnosed. Precision prevention allows clinicians to provide personalized health benefits of smoking cessation.
This is a report on whether smoking cessation confers the same benefits in terms of lung cancer risk reduction for those who possess CHRNA5 risk variants versus those who do not. We determined that quitting smoking is highly beneficial in reducing lung cancer risk levels for smokers regardless of their CHRNA5 rs16969968 genetic risk status. Although CHRNA5 rs16969968 increases risk for earlier lung cancer by 4 years, quitting produces essentially the same benefit for smokers with either high or low genetic risks. Smokers can cut their risk of lung cancer in half and delay its onset by 7 years among those diagnosed. These results are important for smokers to prevent cancer. On average, smokers at all genetic risk levels can largely eliminate their elevated risk for lung cancer by quitting smoking.
Collapse
|
118
|
Abstract
Despite great progress in research and treatment options, lung cancer remains the leading cause of cancer-related deaths worldwide. Oncogenic driver mutations in protein-encoding genes were defined and allow for personalized therapies based on genetic diagnoses. Nonetheless, diagnosis of lung cancer mostly occurs at late stages, and chronic treatment is followed by a fast onset of chemoresistance. Hence, there is an urgent need for reliable biomarkers and alternative treatment options. With the era of whole genome and transcriptome sequencing technologies, long noncoding RNAs emerged as a novel class of versatile, functional RNA molecules. Although for most of them the mechanism of action remains to be defined, accumulating evidence confirms their involvement in various aspects of lung tumorigenesis. They are functional on the epigenetic, transcriptional, and posttranscriptional level and are regulators of pathophysiological key pathways including cell growth, apoptosis, and metastasis. Long noncoding RNAs are gaining increasing attention as potential biomarkers and a novel class of druggable molecules. It has become clear that we are only beginning to understand the complexity of tumorigenic processes. The clinical integration of long noncoding RNAs in terms of prognostic and predictive biomarker signatures and additional cancer targets could provide a chance to increase the therapeutic benefit. Here, we review the current knowledge about the expression, regulation, biological function, and clinical relevance of long noncoding RNAs in lung cancer.
Collapse
Affiliation(s)
- Anna Roth
- Division of RNA Biology and Cancer, German Cancer Research Center (DKFZ) and Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 280 (B150), 69120, Heidelberg, Germany
| | - Sven Diederichs
- Division of RNA Biology and Cancer, German Cancer Research Center (DKFZ) and Institute of Pathology, University Hospital Heidelberg, Im Neuenheimer Feld 280 (B150), 69120, Heidelberg, Germany.
| |
Collapse
|
119
|
Qian DC, Han Y, Byun J, Shin HR, Hung RJ, McLaughlin JR, Landi MT, Seminara D, Amos CI. A Novel Pathway-Based Approach Improves Lung Cancer Risk Prediction Using Germline Genetic Variations. Cancer Epidemiol Biomarkers Prev 2016; 25:1208-15. [PMID: 27222311 DOI: 10.1158/1055-9965.epi-15-1318] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2015] [Accepted: 05/13/2016] [Indexed: 12/29/2022] Open
Abstract
BACKGROUND Although genome-wide association studies (GWAS) have identified many genetic variants that are strongly associated with lung cancer, these variants have low penetrance and serve as poor predictors of lung cancer in individuals. We sought to increase the predictive value of germline variants by considering their cumulative effects in the context of biologic pathways. METHODS For individuals in the Environment and Genetics in Lung Cancer Etiology study (1,815 cases/1,971 controls), we computed pathway-level susceptibility effects as the sum of relevant SNP variant alleles weighted by their log-additive effects from a separate lung cancer GWAS meta-analysis (7,766 cases/37,482 controls). Logistic regression models based on age, sex, smoking, genetic variants, and principal components of pathway effects and pathway-smoking interactions were trained and optimized in cross-validation and further tested on an independent dataset (556 cases/830 controls). We assessed prediction performance using area under the receiver operating characteristic curve (AUC). RESULTS Compared with typical binomial prediction models that have epidemiologic predictors (AUC = 0.607) in addition to top GWAS variants (AUC = 0.617), our pathway-based smoking-interactive multinomial model significantly improved prediction performance in external validation (AUC = 0.656, P < 0.0001). CONCLUSIONS Our biologically informed approach demonstrated a larger increase in AUC over nongenetic counterpart models relative to previous approaches that incorporate variants. IMPACT This model is the first of its kind to evaluate lung cancer prediction using subtype-stratified genetic effects organized into pathways and interacted with smoking. We propose pathway-exposure interactions as a potentially powerful new contributor to risk inference. Cancer Epidemiol Biomarkers Prev; 25(8); 1208-15. ©2016 AACR.
Collapse
Affiliation(s)
- David C Qian
- Department of Biomedical Data Science, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire
| | - Younghun Han
- Department of Biomedical Data Science, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire
| | - Jinyoung Byun
- Department of Biomedical Data Science, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire
| | - Hae Ri Shin
- Department of Biomedical Data Science, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire
| | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada
| | - John R McLaughlin
- Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
| | | | | | - Christopher I Amos
- Department of Biomedical Data Science, Dartmouth Geisel School of Medicine, Lebanon, New Hampshire.
| |
Collapse
|
120
|
Atwater T, Massion PP. Biomarkers of risk to develop lung cancer in the new screening era. ANNALS OF TRANSLATIONAL MEDICINE 2016; 4:158. [PMID: 27195276 DOI: 10.21037/atm.2016.03.46] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Low-dose computed tomography for high-risk individuals has for the first time demonstrated unequivocally that early detection save lives. The currently accepted screening strategy comes at the cost of a high rate of false positive findings while still missing a large percentage of the cases. Therefore, there is increasing interest in developing strategies to better estimate the risk of an individual to develop lung cancer, to increase the sensitivity of the screening process, to reduce screening costs and to reduce the numbers of individuals harmed by screening and follow-up interventions. New molecular biomarkers candidates show promise to improve lung cancer outcomes. This review discusses the current state of biomarker research in lung cancer screening with the primary focus on risk assessment.
Collapse
Affiliation(s)
- Thomas Atwater
- 1 Department of Medicine, 2 Division of Allergy, Pulmonary and Critical Care Medicine, Thoracic Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA ; 3 Veterans Affairs, Tennessee Valley, Healthcare System, Nashville, Tennessee, USA
| | - Pierre P Massion
- 1 Department of Medicine, 2 Division of Allergy, Pulmonary and Critical Care Medicine, Thoracic Program, Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee, USA ; 3 Veterans Affairs, Tennessee Valley, Healthcare System, Nashville, Tennessee, USA
| |
Collapse
|
121
|
Thorgeirsson TE, Steinberg S, Reginsson GW, Bjornsdottir G, Rafnar T, Jonsdottir I, Helgadottir A, Gretarsdottir S, Helgadottir H, Jonsson S, Matthiasson SE, Gislason T, Tyrfingsson T, Gudbjartsson T, Isaksson HJ, Hardardottir H, Sigvaldason A, Kiemeney LA, Haugen A, Zienolddiny S, Wolf HJ, Franklin WA, Panadero A, Mayordomo JI, Hall IP, Rönmark E, Lundbäck B, Dirksen A, Ashraf H, Pedersen JH, Masson G, Sulem P, Thorsteinsdottir U, Gudbjartsson DF, Stefansson K. A rare missense mutation in CHRNA4 associates with smoking behavior and its consequences. Mol Psychiatry 2016; 21:594-600. [PMID: 26952864 PMCID: PMC5414061 DOI: 10.1038/mp.2016.13] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2015] [Revised: 12/17/2015] [Accepted: 01/04/2016] [Indexed: 11/22/2022]
Abstract
Using Icelandic whole-genome sequence data and an imputation approach we searched for rare sequence variants in CHRNA4 and tested them for association with nicotine dependence. We show that carriers of a rare missense variant (allele frequency=0.24%) within CHRNA4, encoding an R336C substitution, have greater risk of nicotine addiction than non-carriers as assessed by the Fagerstrom Test for Nicotine Dependence (P=1.2 × 10(-4)). The variant also confers risk of several serious smoking-related diseases previously shown to be associated with the D398N substitution in CHRNA5. We observed odds ratios (ORs) of 1.7-2.3 for lung cancer (LC; P=4.0 × 10(-4)), chronic obstructive pulmonary disease (COPD; P=9.3 × 10(-4)), peripheral artery disease (PAD; P=0.090) and abdominal aortic aneurysms (AAAs; P=0.12), and the variant associates strongly with the early-onset forms of LC (OR=4.49, P=2.2 × 10(-4)), COPD (OR=3.22, P=2.9 × 10(-4)), PAD (OR=3.47, P=9.2 × 10(-3)) and AAA (OR=6.44, P=6.3 × 10(-3)). Joint analysis of the four smoking-related diseases reveals significant association (P=6.8 × 10(-5)), particularly for early-onset cases (P=2.1 × 10(-7)). Our results are in agreement with functional studies showing that the human α4β2 isoform of the channel containing R336C has less sensitivity for its agonists than the wild-type form following nicotine incubation.
Collapse
Affiliation(s)
| | | | | | | | - T Rafnar
- deCODE genetics/Amgen, Reykjavik, Iceland
| | - I Jonsdottir
- deCODE genetics/Amgen, Reykjavik, Iceland
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland
| | | | | | | | - S Jonsson
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- Department of Respiratory Medicine, Landspitali University Hospital, Reykjavik, Iceland
| | | | - T Gislason
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- Department of Respiratory Medicine, Landspitali University Hospital, Reykjavik, Iceland
| | - T Tyrfingsson
- SAA National Center of Addiction Medicine, Reykjavik, Iceland
| | - T Gudbjartsson
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland
- Department of Cardiothoracic Surgery, Landspitali University Hospital, Reykjavik, Iceland
| | - H J Isaksson
- Department of Pathology, Landspitali University Hospital, Reykjavik, Iceland
| | - H Hardardottir
- Department of Respiratory Medicine, Landspitali University Hospital, Reykjavik, Iceland
| | - A Sigvaldason
- Department of Respiratory Medicine, Landspitali University Hospital, Reykjavik, Iceland
| | - L A Kiemeney
- Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands
- Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands
| | - A Haugen
- Department for the Chemical and Biological Work Environment, National Institute of Occupational Health, Oslo, Norway
| | - S Zienolddiny
- Department for the Chemical and Biological Work Environment, National Institute of Occupational Health, Oslo, Norway
| | - H J Wolf
- Community & Behavioral Health, Colorado School of Public Health, University of Colorado Denver, Aurora, CO, USA
| | - W A Franklin
- Department of Pathology, University of Colorado Denver, Aurora, CO, USA
| | - A Panadero
- Division of Medical Oncology, Hospital Ciudad de Coria, Coria, Spain
| | - J I Mayordomo
- Division of Medical Oncology, University of Colorado School of Medicine, Denver, CO, USA
| | - I P Hall
- Division of Respiratory Medicine, Queens Medical Centre, University of Nottingham, Nottingham, UK
| | - E Rönmark
- The OLIN studies, Department of Medicine, Sunderby Central Hospital of Norrbotten, Luleå, Sweden
- Faculty of Medicine, Department of Public Health and Clinical Medicine, Occupational and Environmental Medicine, Umeå University, Umeå, Sweden
| | - B Lundbäck
- The OLIN studies, Department of Medicine, Sunderby Central Hospital of Norrbotten, Luleå, Sweden
- Krefting Research Centre, Institute of Medicine, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
| | - A Dirksen
- Department of Respiratory Medicine, Gentofte Hospital, Copenhagen University, Hellerup, Denmark
| | - H Ashraf
- Department of Respiratory Medicine, Gentofte Hospital, Copenhagen University, Hellerup, Denmark
- Centre for Diagnostic Imaging—Thoracic Section, Akershus University Hospital, Loerenskog, Norway
| | - J H Pedersen
- Department of Thoracic Surgery RT, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
| | - G Masson
- deCODE genetics/Amgen, Reykjavik, Iceland
| | - P Sulem
- deCODE genetics/Amgen, Reykjavik, Iceland
| | | | | | - K Stefansson
- deCODE genetics/Amgen, Reykjavik, Iceland
- Faculty of Medicine, University of Iceland, Reykjavik, Iceland
| |
Collapse
|
122
|
Erikson GA, Bodian DL, Rueda M, Molparia B, Scott ER, Scott-Van Zeeland AA, Topol SE, Wineinger NE, Niederhuber JE, Topol EJ, Torkamani A. Whole-Genome Sequencing of a Healthy Aging Cohort. Cell 2016; 165:1002-11. [PMID: 27114037 DOI: 10.1016/j.cell.2016.03.022] [Citation(s) in RCA: 137] [Impact Index Per Article: 17.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2015] [Revised: 02/05/2016] [Accepted: 03/14/2016] [Indexed: 01/23/2023]
Abstract
Studies of long-lived individuals have revealed few genetic mechanisms for protection against age-associated disease. Therefore, we pursued genome sequencing of a related phenotype-healthy aging-to understand the genetics of disease-free aging without medical intervention. In contrast with studies of exceptional longevity, usually focused on centenarians, healthy aging is not associated with known longevity variants, but is associated with reduced genetic susceptibility to Alzheimer and coronary artery disease. Additionally, healthy aging is not associated with a decreased rate of rare pathogenic variants, potentially indicating the presence of disease-resistance factors. In keeping with this possibility, we identify suggestive common and rare variant genetic associations implying that protection against cognitive decline is a genetic component of healthy aging. These findings, based on a relatively small cohort, require independent replication. Overall, our results suggest healthy aging is an overlapping but distinct phenotype from exceptional longevity that may be enriched with disease-protective genetic factors. VIDEO ABSTRACT.
Collapse
Affiliation(s)
- Galina A Erikson
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Dale L Bodian
- Inova Translational Medicine Institute, Inova Health System, Falls Church, VA 22042 USA
| | - Manuel Rueda
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Bhuvan Molparia
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Erick R Scott
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA
| | | | - Sarah E Topol
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA
| | - Nathan E Wineinger
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA
| | - John E Niederhuber
- Inova Translational Medicine Institute, Inova Health System, Falls Church, VA 22042 USA; Department of Oncology, School of Medicine, Johns Hopkins University, Baltimore, MD 21205, USA
| | - Eric J Topol
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA.
| | - Ali Torkamani
- The Scripps Translational Science Institute, Scripps Health, and The Scripps Research Institute, La Jolla, CA 92037, USA; Cypher Genomics, Inc., San Diego, CA 92121, USA.
| |
Collapse
|
123
|
Kang X, Liu H, Onaitis MW, Liu Z, Owzar K, Han Y, Su L, Wei Y, Hung RJ, Brhane Y, McLaughlin J, Brennan P, Bickeböller H, Rosenberger A, Houlston RS, Caporaso N, Landi MT, Heinrich J, Risch A, Wu X, Ye Y, Christiani DC, Amos CI, Wei Q. Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. Carcinogenesis 2016; 37:280-289. [PMID: 26905588 PMCID: PMC4804128 DOI: 10.1093/carcin/bgw014] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2015] [Revised: 01/06/2016] [Accepted: 01/25/2016] [Indexed: 12/31/2022] Open
Abstract
Centrosome abnormalities are often observed in premalignant lesions and in situ tumors and have been associated with aneuploidy and tumor development. We investigated the associations of 9354 single-nucleotide polymorphisms (SNPs) in 106 centrosomal genes with lung cancer risk by first using the summary data from six published genome-wide association studies (GWASs) of the Transdisciplinary Research in Cancer of the Lung (TRICL) (12,160 cases and 16 838 controls) and then conducted in silico replication in two additional independent lung cancer GWASs of Harvard University (984 cases and 970 controls) and deCODE (1319 cases and 26,380 controls). A total of 44 significant SNPs with false discovery rate (FDR) ≤ 0.05 were mapped to one novel gene FGFR1OP and two previously reported genes (TUBB and BRCA2). After combined the results from TRICL with those from Harvard and deCODE, the most significant association (P combined = 8.032 × 10(-6)) was with rs151606 within FGFR1OP. The rs151606 T>G was associated with an increased risk of lung cancer [odds ratio (OR) = 1.10, 95% confidence interval (95% CI) = 1.05-1.14]. Another significant tagSNP rs12212247 T>C (P combined = 9.589 × 10(-6)) was associated with a decreased risk of lung cancer (OR = 0.93, 95% CI = 0.90-0.96). Further in silico functional analyzes revealed that rs151606 might affect transcriptional regulation and result in decreased FGFR1OP expression (P trend = 0.022). The findings shed some new light on the role of centrosome abnormalities in the susceptibility to lung carcinogenesis.
Collapse
Affiliation(s)
- Xiaozheng Kang
- Duke Cancer Institute and
- Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, 905 S. LaSalle Street, Durham, NC 27710, USA
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China
| | - Hongliang Liu
- Duke Cancer Institute and
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Mark W. Onaitis
- Duke Cancer Institute and
- Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, 905 S. LaSalle Street, Durham, NC 27710, USA
| | - Zhensheng Liu
- Duke Cancer Institute and
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Kouros Owzar
- Duke Cancer Institute and
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
| | - Younghun Han
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Li Su
- Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
| | - Yongyue Wei
- Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
| | - Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Yonathan Brhane
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
| | | | - Paul Brennan
- Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), 69372 Lyon, France
| | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
| | - Albert Rosenberger
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
| | - Richard S. Houlston
- Division of Genetics and Epidemiology, the Institute of Cancer Research, London SW7 3RP, UK
| | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Joachim Heinrich
- Helmholtz Centre Munich, German Research Centre for Environmental Health, Institute of Epidemiology I, 85764 Neuherberg, Germany
| | - Angela Risch
- Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria and
| | - Xifeng Wu
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Yuanqing Ye
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - David C. Christiani
- Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
| | - Christopher I. Amos
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
| | - Qingyi Wei
- Duke Cancer Institute and
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
| | - Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team
- Duke Cancer Institute and
- Division of Cardiovascular and Thoracic Surgery, Department of Surgery, Duke University Medical Center, 905 S. LaSalle Street, Durham, NC 27710, USA
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Thoracic Surgery I, Peking University Cancer Hospital and Institute, Beijing 100142, China
- Department of Medicine, Duke University School of Medicine, Durham, NC 27710, USA
- Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC 27710, USA
- Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA
- Massachusetts General Hospital, Boston, MA 02114, USA
- Department of Environmental Health, Harvard School of Public Health, Boston, MA 02115, USA
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario, Canada
- Public Health Ontario, Toronto, Ontario M5T 3L9, Canada
- Genetic Epidemiology Group, International Agency for Research on Cancer (IARC), 69372 Lyon, France
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
- Division of Genetics and Epidemiology, the Institute of Cancer Research, London SW7 3RP, UK
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
- Helmholtz Centre Munich, German Research Centre for Environmental Health, Institute of Epidemiology I, 85764 Neuherberg, Germany
- Department of Molecular Biology, University of Salzburg, 5020 Salzburg, Austria and
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| |
Collapse
|
124
|
Abstract
As our understanding of genetics has improved, genome-wide association studies (GWAS) have identified numerous variants associated with lifestyle behaviours and health outcomes. However, what is sometimes overlooked is the possibility that genetic variants identified in GWAS of disease might reflect the effect of modifiable risk factors as well as direct genetic effects. We discuss this possibility with illustrative examples from tobacco and alcohol research, in which genetic variants that predict behavioural phenotypes have been seen in GWAS of diseases known to be causally related to these behaviours. This consideration has implications for the interpretation of GWAS findings.
Collapse
Affiliation(s)
- Suzanne H. Gage
- MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, United Kingdom
- UK Centre for Tobacco and Alcohol Studies, School of Experimental Psychology, University of Bristol, Bristol, United Kingdom
| | - George Davey Smith
- MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, United Kingdom
- School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Jennifer J. Ware
- MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, United Kingdom
- School of Social and Community Medicine, University of Bristol, Bristol, United Kingdom
| | - Jonathan Flint
- Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, United Kingdom
| | - Marcus R. Munafò
- MRC Integrative Epidemiology Unit (IEU) at the University of Bristol, Bristol, United Kingdom
- UK Centre for Tobacco and Alcohol Studies, School of Experimental Psychology, University of Bristol, Bristol, United Kingdom
| |
Collapse
|
125
|
Qu X, Wang K, Dong W, Shen H, Wang Y, Liu Q, Du J. Association between two CHRNA3 variants and susceptibility of lung cancer: a meta-analysis. Sci Rep 2016; 6:20149. [PMID: 26831765 PMCID: PMC4735583 DOI: 10.1038/srep20149] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2015] [Accepted: 12/30/2015] [Indexed: 02/07/2023] Open
Abstract
Genome-wide association studies (GWAS) have identified two CHRNA3 polymorphisms (rs578776 and rs938682) associated with lung cancer risk. Furthermore, these polymorphisms were investigated and genotyped by PCR analysis. All eligible case-control studies published up to Mar 1st 2015 were identified by searching Pubmed and Embase database. Negative association between rs578776-T allele and risk of lung cancer was obtained without obvious heterogeneity (OR: 0.83, 95% CI: 0.79-0.86; p = 0.898 for Q test). Rs938682-C allele carriers had a 12% to 28% decreased risk. Genotype model analysis showed results of dominant model for rs578776 (OR with 95% CI: 0.839(0.718-0.981)), dominant model for rs938682 (OR with 95% CI: 0.778(0.663-0.912)) and homozygous model for rs938682 (OR with 95% CI: 0.767(0.708-0.831)) were statistically significant. Subgroup analysis indicated rs578776-T variant had protective effect in Smokers, Caucasians, two histology subgroups, and two match subgroups. Meanwhile, rs938682-C allele was associated with decreased risk in Smokers, Caucasians, Lung cancer, and two match subgroups. Meta-regression suggested ethnicity might be the major source of heterogeneity in allele model and homozygous model for rs938682. Moreover, smoking status might contribute to part of heterogeneity under allele model. In summary, this meta-analysis suggested both rs578776 and rs938682 were significantly associated with the susceptibility of lung cancer.
Collapse
Affiliation(s)
- Xiao Qu
- Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| | - Kai Wang
- Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| | - Wei Dong
- Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| | - Hongchang Shen
- Department of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| | - Ying Wang
- Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| | - Qi Liu
- Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| | - Jiajun Du
- Institute of Oncology, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
- Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Shandong University, 324 Jingwu Road, Jinan, 250021 P.R. China
| |
Collapse
|
126
|
Wang Z, Seow WJ, Shiraishi K, Hsiung CA, Matsuo K, Liu J, Chen K, Yamji T, Yang Y, Chang IS, Wu C, Hong YC, Burdett L, Wyatt K, Chung CC, Li SA, Yeager M, Hutchinson A, Hu W, Caporaso N, Landi MT, Chatterjee N, Song M, Fraumeni JF, Kohno T, Yokota J, Kunitoh H, Ashikawa K, Momozawa Y, Daigo Y, Mitsudomi T, Yatabe Y, Hida T, Hu Z, Dai J, Ma H, Jin G, Song B, Wang Z, Cheng S, Yin Z, Li X, Ren Y, Guan P, Chang J, Tan W, Chen CJ, Chang GC, Tsai YH, Su WC, Chen KY, Huang MS, Chen YM, Zheng H, Li H, Cui P, Guo H, Xu P, Liu L, Iwasaki M, Shimazu T, Tsugane S, Zhu J, Jiang G, Fei K, Park JY, Kim YH, Sung JS, Park KH, Kim YT, Jung YJ, Kang CH, Park IK, Kim HN, Jeon HS, Choi JE, Choi YY, Kim JH, Oh IJ, Kim YC, Sung SW, Kim JS, Yoon HI, Kweon SS, Shin MH, Seow A, Chen Y, Lim WY, Liu J, Wong MP, Lee VHF, Bassig BA, Tucker M, Berndt SI, Chow WH, Ji BT, Wang J, Xu J, Sihoe ADL, Ho JCM, Chan JKC, Wang JC, Lu D, Zhao X, Zhao Z, Wu J, Chen H, Jin L, Wei F, Wu G, An SJ, Zhang XC, Su J, Wu YL, Gao YT, Xiang YB, He X, Li J, Zheng W, Shu XO, Cai Q, Klein R, Pao W, Lawrence C, Hosgood HD, Hsiao CF, Chien LH, Chen YH, Chen CH, Wang WC, Chen CY, Wang CL, Yu CJ, Chen HL, Su YC, Tsai FY, Chen YS, Li YJ, Yang TY, Lin CC, Yang PC, Wu T, Lin D, Zhou B, Yu J, Shen H, Kubo M, Chanock SJ, Rothman N, Lan Q. Meta-analysis of genome-wide association studies identifies multiple lung cancer susceptibility loci in never-smoking Asian women. Hum Mol Genet 2016; 25:620-9. [PMID: 26732429 PMCID: PMC4731021 DOI: 10.1093/hmg/ddv494] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2015] [Revised: 10/30/2015] [Accepted: 11/26/2015] [Indexed: 12/20/2022] Open
Abstract
Genome-wide association studies (GWAS) of lung cancer in Asian never-smoking women have previously identified six susceptibility loci associated with lung cancer risk. To further discover new susceptibility loci, we imputed data from four GWAS of Asian non-smoking female lung cancer (6877 cases and 6277 controls) using the 1000 Genomes Project (Phase 1 Release 3) data as the reference and genotyped additional samples (5878 cases and 7046 controls) for possible replication. In our meta-analysis, three new loci achieved genome-wide significance, marked by single nucleotide polymorphism (SNP) rs7741164 at 6p21.1 (per-allele odds ratio (OR) = 1.17; P = 5.8 × 10(-13)), rs72658409 at 9p21.3 (per-allele OR = 0.77; P = 1.41 × 10(-10)) and rs11610143 at 12q13.13 (per-allele OR = 0.89; P = 4.96 × 10(-9)). These findings identified new genetic susceptibility alleles for lung cancer in never-smoking women in Asia and merit follow-up to understand their biological underpinnings.
Collapse
Affiliation(s)
- Zhaoming Wang
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA,
| | - Wei Jie Seow
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Kouya Shiraishi
- Division of Genome Biology, National Cancer Center Hospital, Tokyo, Japan
| | | | - Keitaro Matsuo
- Division of Molecular Medicine, Aichi Cancer Center Research Institute, Nagoya, Japan
| | - Jie Liu
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China
| | - Kexin Chen
- Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Taiki Yamji
- Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
| | - Yang Yang
- Shanghai Pulmonary Hospital, Shanghai, China
| | - I-Shou Chang
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | - Chen Wu
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | - Laurie Burdett
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Kathleen Wyatt
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Charles C Chung
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Shengchao A Li
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Meredith Yeager
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Amy Hutchinson
- Cancer Genomics Research Laboratory, Leidos Biomedical Research Inc., Gaithersburg, MD, USA, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Wei Hu
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Neil Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Maria T Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Nilanjan Chatterjee
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Minsun Song
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Joseph F Fraumeni
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Takashi Kohno
- Division of Genome Biology, National Cancer Center Hospital, Tokyo, Japan
| | - Jun Yokota
- Cancer Genome Biology Group, Institute of Predictive and Personalized Medicine of Cancer, Barcelona, Spain
| | - Hideo Kunitoh
- Department of Medical Oncology, Japanese Red Cross Medical Center, Tokyo, Japan
| | - Kyota Ashikawa
- Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yukihide Momozawa
- Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Yataro Daigo
- Laboratory of Molecular Medicine, Human Genome Center, Institute of Medical Science, University of Tokyo, Tokyo, Japan
| | - Tetsuya Mitsudomi
- Division of Thoracic Surgery, Kinki University School of Medicine, Sayama, Japan
| | | | - Toyoaki Hida
- Department of Thoracic Oncology, Aichi Cancer Center Central Hospital, Nagoya, Japan
| | - Zhibin Hu
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Juncheng Dai
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Hongxia Ma
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Guangfu Jin
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Bao Song
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China
| | - Zhehai Wang
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China
| | - Sensen Cheng
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China
| | - Zhihua Yin
- Department of Epidemiology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, China, Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China
| | - Xuelian Li
- Department of Epidemiology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, China, Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China
| | - Yangwu Ren
- Department of Epidemiology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, China, Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China
| | - Peng Guan
- Department of Epidemiology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, China, Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China
| | - Jiang Chang
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Wen Tan
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Chien-Jen Chen
- Genomic Research Center, Academia Sinica, Taipei, Taiwan
| | - Gee-Chen Chang
- Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan, Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Ying-Huang Tsai
- Division of Pulmonary and Critical Care Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, Taiwan
| | - Wu-Chou Su
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Kuan-Yu Chen
- Division of Pulmonary Medicine, Department of Internal Medicine, National Taiwan University Hospital and College of Medicine, National Taiwan University, Taipei, Taiwan
| | - Ming-Shyan Huang
- Department of Internal Medicine, Kaohsiung Medical University Hospital, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
| | - Yuh-Min Chen
- Department of Chest Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, College of Medical Science and Technology
| | - Hong Zheng
- Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Haixin Li
- Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Ping Cui
- Department of Epidemiology and Biostatistics, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
| | - Huan Guo
- Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College
| | - Ping Xu
- Department of Oncology, Wuhan Iron and Steel (Group) Corporation Staff-Worker Hospital, Wuhan, China
| | - Li Liu
- Department of Oncology, Cancer Center, Union Hospital, Huazhong University of Science and Technology, Wuhan, China
| | - Motoki Iwasaki
- Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
| | - Taichi Shimazu
- Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
| | - Shoichiro Tsugane
- Epidemiology and Prevention Group, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
| | - Junjie Zhu
- Shanghai Pulmonary Hospital, Shanghai, China
| | | | - Ke Fei
- Shanghai Pulmonary Hospital, Shanghai, China
| | | | - Yeul Hong Kim
- Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
| | - Jae Sook Sung
- Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
| | - Kyong Hwa Park
- Department of Internal Medicine, Division of Oncology/Hematology, College of Medicine, Korea University Anam Hospital, Seoul, Republic of Korea
| | - Young Tae Kim
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Yoo Jin Jung
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Chang Hyun Kang
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - In Kyu Park
- Department of Thoracic and Cardiovascular Surgery, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Hee Nam Kim
- Center for Creative Biomedical Scientists, Chonnam National University, Gwangju, Republic of Korea
| | - Hyo-Sung Jeon
- Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Jin Eun Choi
- Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Yi Young Choi
- Cancer Research Center, Kyungpook National University Medical Center, Daegu, Republic of Korea
| | - Jin Hee Kim
- Department of Environmental Health, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea
| | - In-Jae Oh
- Lung and Esophageal Cancer Clinic, Department of Internal Medicine
| | - Young-Chul Kim
- Lung and Esophageal Cancer Clinic, Department of Internal Medicine
| | | | - Jun Suk Kim
- Department of Internal Medicine, Division of Medical Oncology, College of Medicine, Korea University Guro Hospital, Seoul, Republic of Korea
| | - Ho-Il Yoon
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea
| | - Sun-Seog Kweon
- Jeonnam Regional Cancer Center, Chonnam National University Hwasun Hospital, Hwasun-eup, Republic of Korea, Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Min-Ho Shin
- Department of Preventive Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea
| | - Adeline Seow
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Ying Chen
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Wei-Yen Lim
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore
| | - Jianjun Liu
- Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, Department of Human Genetics, Genome Institute of Singapore, Singapore, Singapore, School of Life Sciences, Anhui Medical University, Hefei, China
| | - Maria Pik Wong
- Department of Pathology, Li Ka Shing (LKS) Faculty of Medicine
| | | | - Bryan A Bassig
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Margaret Tucker
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Sonja I Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Wong-Ho Chow
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Bu-Tian Ji
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Junwen Wang
- Department of Biochemistry, LKS Faculty of Medicine, Centre for Genomic Sciences, LKS Faculty of Medicine
| | - Jun Xu
- School of Public Health, Li Ka Shing (LKS) Faculty of Medicine
| | | | - James C M Ho
- Department of Medicine, Li Ka Shing (LKS) Faculty of Medicine, The University of Hong Kong, Hong Kong, China
| | - John K C Chan
- Department of Pathology, Queen Elizabeth Hospital, Hong Kong, China
| | - Jiu-Cun Wang
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Daru Lu
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Xueying Zhao
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Zhenhong Zhao
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Junjie Wu
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Hongyan Chen
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Li Jin
- Ministry of Education Key Laboratory of Contemporary Anthropology, State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, China
| | - Fusheng Wei
- China National Environmental Monitoring Center, Beijing, China
| | - Guoping Wu
- China National Environmental Monitoring Center, Beijing, China
| | - She-Juan An
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Xu-Chao Zhang
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Jian Su
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Yi-Long Wu
- Guangdong Lung Cancer Institute, Medical Research Center and Cancer Center of Guangdong General Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China
| | - Yu-Tang Gao
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China
| | - Yong-Bing Xiang
- Department of Epidemiology, Shanghai Cancer Institute, Shanghai, China
| | - Xingzhou He
- Chinese Center for Disease Control and Prevention, Beijing, China
| | - Jihua Li
- Qujing Center for Diseases Control and Prevention, Sanjiangdadao, Qujing, China
| | - Wei Zheng
- Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
| | - Xiao-Ou Shu
- Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
| | - Qiuyin Cai
- Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA
| | - Robert Klein
- Program in Cancer Biology and Genetics, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
| | - William Pao
- Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA
| | | | - H Dean Hosgood
- Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA
| | | | | | | | - Chung-Hsing Chen
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | - Wen-Chang Wang
- The PhD Program for Translational Medicine, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
| | - Chih-Yi Chen
- Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan, Division of Thoracic Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan and
| | - Chih-Liang Wang
- Department of Pulmonary and Critical Care, Chang Gung Memorial Hospital, Taoyuan, Taiwan
| | - Chong-Jen Yu
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | | | | | - Fang-Yu Tsai
- National Institute of Cancer Research, National Health Research Institutes, Zhunan, Taiwan
| | | | - Yao-Jen Li
- Genomic Research Center, Academia Sinica, Taipei, Taiwan
| | - Tsung-Ying Yang
- Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan
| | - Chien-Chung Lin
- Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan
| | - Pan-Chyr Yang
- Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan
| | - Tangchun Wu
- Department of Occupational and Environmental Health and Ministry of Education Key Lab for Environment and Health, School of Public Health, Tongji Medical College
| | - Dongxin Lin
- Department of Etiology & Carcinogenesis and State Key Laboratory of Molecular Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | - Baosen Zhou
- Department of Epidemiology, School of Public Health, China Medical University, No. 77 Puhe Road, Shenyang North New Area, Shenyang, China, Key Laboratory of Cancer Etiology and Intervention, University of Liaoning Province, Shenyang, China
| | - Jinming Yu
- Department of Oncology, Shandong Cancer Hospital and Institute, Shandong Academy of Medical Sciences, Jinan, China
| | - Hongbing Shen
- Department of Epidemiology and Biostatistics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
| | - Michiaki Kubo
- Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan
| | - Stephen J Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Nathaniel Rothman
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| | - Qing Lan
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
| |
Collapse
|
127
|
Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, Hung RJ, Sellers TA, Witte JS, Pharoah P, Henderson BE, Gruber SB, Hunter DJ, Garber JE, Joshi AD, McDonnell K, Easton DF, Eeles R, Kote-Jarai Z, Muir K, Doherty JA, Schildkraut JM. A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. Cancer Epidemiol Biomarkers Prev 2016; 25:193-200. [PMID: 26637267 PMCID: PMC4713268 DOI: 10.1158/1055-9965.epi-15-0649] [Citation(s) in RCA: 60] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/16/2015] [Accepted: 10/05/2015] [Indexed: 01/22/2023] Open
Abstract
BACKGROUND DNA damage is an established mediator of carcinogenesis, although genome-wide association studies (GWAS) have identified few significant loci. This cross-cancer site, pooled analysis was performed to increase the power to detect common variants of DNA repair genes associated with cancer susceptibility. METHODS We conducted a cross-cancer analysis of 60,297 single nucleotide polymorphisms, at 229 DNA repair gene regions, using data from the NCI Genetic Associations and Mechanisms in Oncology (GAME-ON) Network. Our analysis included data from 32 GWAS and 48,734 controls and 51,537 cases across five cancer sites (breast, colon, lung, ovary, and prostate). Because of the unavailability of individual data, data were analyzed at the aggregate level. Meta-analysis was performed using the Association analysis for SubSETs (ASSET) software. To test for genetic associations that might escape individual variant testing due to small effect sizes, pathway analysis of eight DNA repair pathways was performed using hierarchical modeling. RESULTS We identified three susceptibility DNA repair genes, RAD51B (P < 5.09 × 10(-6)), MSH5 (P < 5.09 × 10(-6)), and BRCA2 (P = 5.70 × 10(-6)). Hierarchical modeling identified several pleiotropic associations with cancer risk in the base excision repair, nucleotide excision repair, mismatch repair, and homologous recombination pathways. CONCLUSIONS Only three susceptibility loci were identified, which had all been previously reported. In contrast, hierarchical modeling identified several pleiotropic cancer risk associations in key DNA repair pathways. IMPACT Results suggest that many common variants in DNA repair genes are likely associated with cancer susceptibility through small effect sizes that do not meet stringent significance testing criteria.
Collapse
Affiliation(s)
- Peter M Scarbrough
- Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina. Cancer Prevention, Detection, and Control Research Program, Duke Cancer Institute, Durham, North Carolina. Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, North Carolina
| | - Rachel Palmieri Weber
- Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina. Cancer Prevention, Detection, and Control Research Program, Duke Cancer Institute, Durham, North Carolina
| | - Edwin S Iversen
- Department of Statistical Science, Duke University, Durham, North Carolina
| | - Yonathan Brhane
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| | | | - Peter Kraft
- Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts
| | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Thomas A Sellers
- Department of Cancer Epidemiology, Moffitt Cancer Center, Tampa, Florida
| | - John S Witte
- Institute for Human Genetics, University of California, San Francisco, San Francisco, California. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
| | - Paul Pharoah
- Department of Oncology, University of Cambridge, Cambridge, United Kingdom. Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Brian E Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | - Stephen B Gruber
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | - David J Hunter
- Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts
| | - Judy E Garber
- Cancer Risk and Prevention Clinic, Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Amit D Joshi
- Program in Genetic Epidemiology and Statistical Genetics, Harvard School of Public Health, Boston, Massachusetts
| | - Kevin McDonnell
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California
| | - Doug F Easton
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
| | - Ros Eeles
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom. Royal Marsden NHS Foundation Trust, London and Sutton, United Kingdom
| | - Zsofia Kote-Jarai
- Division of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom. Royal Marsden NHS Foundation Trust, London and Sutton, United Kingdom
| | - Kenneth Muir
- Institute of Population Health, University of Manchester, Manchester, United Kingdom. Warwick Medical School, University of Warwick, Coventry, United Kingdom
| | | | - Joellen M Schildkraut
- Department of Community and Family Medicine, Duke University Medical Center, Durham, North Carolina. Cancer Prevention, Detection, and Control Research Program, Duke Cancer Institute, Durham, North Carolina. Department of Public Health Sciences, University of Virginia, Charlottesville, Virginia.
| |
Collapse
|
128
|
Abstract
PURPOSE OF REVIEW Lung cancer remains the most frequent cancer worldwide and the leading cause of cancer death in most countries. The molecular characteristics of lung tumors play an important role in clinical decisions, which ultimately affect patients' survival. This review aims to summarize the most recent genomic discoveries made on lung cancer. RECENT FINDINGS A relatively comprehensive molecular characterization has been achieved for the three major types of lung cancer: adenocarcinoma, squamous-cell carcinoma, and small-cell carcinoma. Little is still known about large-cell neuroendocrine carcinoma and carcinoid tumors. A major finding has been the nonnegligible inter and intratumor heterogeneity of lung cancer and their impact in the clinical management of this disease. SUMMARY The high load of mutations, the frequent inactivation of major tumor suppressor genes, and the huge heterogeneity of lung cancer tumors may complicate long-lasting therapeutic responses. The development of strategies for the early detection of lung cancer might translate into an increase of the number of surgical resectable tumors, and therefore contribute to improve the survival rate of these patients.
Collapse
Affiliation(s)
- Lynnette Fernandez-Cuesta
- Group of Genetic Cancer Susceptibility, Section of Genetics, International Agency for Research on Cancer (IARC-WHO), Lyon, France
| | | |
Collapse
|
129
|
Schwartz AG, Cote ML. Epidemiology of Lung Cancer. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2016; 893:21-41. [PMID: 26667337 DOI: 10.1007/978-3-319-24223-1_2] [Citation(s) in RCA: 122] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Lung cancer continues to be one of the most common causes of cancer death despite understanding the major cause of the disease: cigarette smoking. Smoking increases lung cancer risk 5- to 10-fold with a clear dose-response relationship. Exposure to environmental tobacco smoke among nonsmokers increases lung cancer risk about 20%. Risks for marijuana and hookah use, and the new e-cigarettes, are yet to be consistently defined and will be important areas for continued research as use of these products increases. Other known environmental risk factors include exposures to radon, asbestos, diesel, and ionizing radiation. Host factors have also been associated with lung cancer risk, including family history of lung cancer, history of chronic obstructive pulmonary disease and infections. Studies to identify genes associated with lung cancer susceptibility have consistently identified chromosomal regions on 15q25, 6p21 and 5p15 associated with lung cancer risk. Risk prediction models for lung cancer typically include age, sex, cigarette smoking intensity and/or duration, medical history, and occupational exposures, however there is not yet a risk prediction model currently recommended for general use. As lung cancer screening becomes more widespread, a validated model will be needed to better define risk groups to inform screening guidelines.
Collapse
Affiliation(s)
- Ann G Schwartz
- Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA.
| | - Michele L Cote
- Department of Oncology, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, USA
| |
Collapse
|
130
|
Kachuri L, Amos CI, McKay JD, Johansson M, Vineis P, Bueno-de-Mesquita H, Boutron-Ruault MC, Johansson M, Quirós J, Sieri S, Travis RC, Weiderpass E, Le Marchand L, Henderson BE, Wilkens L, Goodman GE, Chen C, Doherty JA, Christiani DC, Wei Y, Su L, Tworoger S, Zhang X, Kraft P, Zaridze D, Field JK, Marcus MW, Davies MP, Hyde R, Caporaso NE, Landi MT, Severi G, Giles GG, Liu G, McLaughlin JR, Li Y, Xiao X, Fehringer G, Zong X, Denroche RE, Zuzarte PC, McPherson JD, Brennan P, Hung RJ. Fine mapping of chromosome 5p15.33 based on a targeted deep sequencing and high density genotyping identifies novel lung cancer susceptibility loci. Carcinogenesis 2016; 37:96-105. [PMID: 26590902 PMCID: PMC4715236 DOI: 10.1093/carcin/bgv165] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2015] [Revised: 11/02/2015] [Accepted: 11/13/2015] [Indexed: 01/01/2023] Open
Abstract
Chromosome 5p15.33 has been identified as a lung cancer susceptibility locus, however the underlying causal mechanisms were not fully elucidated. Previous fine-mapping studies of this locus have relied on imputation or investigated a small number of known, common variants. This study represents a significant advance over previous research by investigating a large number of novel, rare variants, as well as their underlying mechanisms through telomere length. Variants for this fine-mapping study were identified through a targeted deep sequencing (average depth of coverage greater than 4000×) of 576 individuals. Subsequently, 4652 SNPs, including 1108 novel SNPs, were genotyped in 5164 cases and 5716 controls of European ancestry. After adjusting for known risk loci, rs2736100 and rs401681, we identified a new, independent lung cancer susceptibility variant in LPCAT1: rs139852726 (OR = 0.46, P = 4.73×10(-9)), and three new adenocarcinoma risk variants in TERT: rs61748181 (OR = 0.53, P = 2.64×10(-6)), rs112290073 (OR = 1.85, P = 1.27×10(-5)), rs138895564 (OR = 2.16, P = 2.06×10(-5); among young cases, OR = 3.77, P = 8.41×10(-4)). In addition, we found that rs139852726 (P = 1.44×10(-3)) was associated with telomere length in a sample of 922 healthy individuals. The gene-based SKAT-O analysis implicated TERT as the most relevant gene in the 5p15.33 region for adenocarcinoma (P = 7.84×10(-7)) and lung cancer (P = 2.37×10(-5)) risk. In this largest fine-mapping study to investigate a large number of rare and novel variants within 5p15.33, we identified novel lung and adenocarcinoma susceptibility loci with large effects and provided support for the role of telomere length as the potential underlying mechanism.
Collapse
Affiliation(s)
- Linda Kachuri
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5T 3M7, Canada
| | - Christopher I. Amos
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - James D. McKay
- International Agency for Research on Cancer, Lyon, CEDEX 08, 69372, France
| | - Mattias Johansson
- International Agency for Research on Cancer, Lyon, CEDEX 08, 69372, France
| | - Paolo Vineis
- Human Genetics Foundation (HuGeF), 10126Torino, Italy
- Department of Epidemiology and Biostatistics, MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, Norfolk Place, London W2 1PG, UK
| | - H.Bas Bueno-de-Mesquita
- Department for Determinants of Chronic Diseases (DCD), National Institute for Public Health and the Environment (RIVM), 3721 MA Bilthoven, The Netherlands
- Department of Gastroenterology and Hepatology, University Medical Centre, 3584 CX Utrecht, The Netherlands
- Department of Epidemiology and Biostatistics, The School of Public Health, Imperial College London, London SW7 2AZ, UK
- Department of Social and Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur 50603, Malaysia
| | - Marie-Christine Boutron-Ruault
- INSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018, Lifestyle, Genes and Health: Integrative Trans-Generational Epidemiology, 94805 Villejuif, France
- Université Paris Sud, UMRS 1018 94805, Villejuif, France
- Institut Gustave RoussyF-94805, Villejuif, France
| | - Mikael Johansson
- Department of Radiation Sciences, Umeå University, Umeå SE-901 87, Sweden
| | - J.Ramón Quirós
- Public Health Directorate Asturias, CP 33006 Oviedo, Spain
| | - Sabina Sieri
- Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milano, Italy
| | - Ruth C. Travis
- Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford OX3 7LF, UK
| | - Elisabete Weiderpass
- Department of Community Medicine, Faculty of Health Sciences, University of Tromsø, The Arctic University of Norway, 9037 Tromsø, Norway
- Department of Research, Cancer Registry of Norway, 0379 Oslo, Norway
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm SE-171 77, Sweden
- Genetic Epidemiology Group, Folkhälsan Research Center, Helsinki FI-00014, Finland
| | | | | | - Lynne Wilkens
- University of Hawaii Cancer Center, Honolulu, HI 96813, USA
| | - Gary E. Goodman
- Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Chu Chen
- Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Jennifer A. Doherty
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - David C. Christiani
- Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
- Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
| | - Yongyue Wei
- Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
| | - Li Su
- Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
| | - Shelley Tworoger
- Departments of Environmental Health and Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
- Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - Xuehong Zhang
- Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - Peter Kraft
- Departments of Biostatistics and Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA
| | - David Zaridze
- Russian Cancer Research Center, Moscow 115478, Russia
| | - John K. Field
- Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
| | - Michael W. Marcus
- Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
| | - Michael P.A. Davies
- Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
| | - Russell Hyde
- Roy Castle Lung Cancer Research Programme, University of Liverpool Cancer Research Centre Institute of Translational Medicine, University of Liverpool, Liverpool L69 3BX, UK
| | - Neil E. Caporaso
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
| | - Gianluca Severi
- Human Genetics Foundation (HuGeF), 10126Torino, Italy
- INSERM, Centre for Research in Epidemiology and Population Health (CESP), U1018, Lifestyle, Genes and Health: Integrative Trans-Generational Epidemiology, 94805 Villejuif, France
- Université Paris Sud, UMRS 1018 94805, Villejuif, France
- Institut Gustave RoussyF-94805, Villejuif, France
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne 3004, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne 3010, Australia
| | - Graham G. Giles
- Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne 3004, Australia
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne 3010, Australia
- Department of Epidemiology and Preventive Medicine, Monash University, Melbourne 3004, Australia
| | - Geoffrey Liu
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5T 3M7, Canada
- Ontario Cancer Institute, Princess Margaret Cancer Center, Toronto, Ontario M5G 0A3, Canada
| | - John R. McLaughlin
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
- Public Health Ontario, Toronto, Ontario M5G 1V2, Canada, and
| | - Yafang Li
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - Xiangjun Xiao
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - Gord Fehringer
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
| | - Xuchen Zong
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
| | - Robert E. Denroche
- Genome Technologies, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada
| | - Philip C. Zuzarte
- Genome Technologies, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada
| | - John D. McPherson
- Genome Technologies, Ontario Institute for Cancer Research, Toronto, Ontario M5G 0A3, Canada
| | - Paul Brennan
- International Agency for Research on Cancer, Lyon, CEDEX 08, 69372, France
| | - Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
- Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario M5T 3M7, Canada
| |
Collapse
|
131
|
Ahmad A, Jafar A, Alshatti Y. PI3K/MEK pathway-targeted therapy in non-small cell lung carcinoma. COGENT MEDICINE 2015. [DOI: 10.1080/2331205x.2015.1114709] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
Affiliation(s)
- Ali Ahmad
- Department of Internal Medicine, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait
| | - Ali Jafar
- Department of Surgical & Interventional Sciences, University College London (UCL), London, UK
- Division of Surgical and Interventional Sciences, Royal Free Hospital, London, UK
| | - Yaqoub Alshatti
- Department of Internal Medicine, Mubarak Al-Kabeer Hospital, Jabriya, Kuwait
| |
Collapse
|
132
|
Fortney K, Dobriban E, Garagnani P, Pirazzini C, Monti D, Mari D, Atzmon G, Barzilai N, Franceschi C, Owen AB, Kim SK. Genome-Wide Scan Informed by Age-Related Disease Identifies Loci for Exceptional Human Longevity. PLoS Genet 2015; 11:e1005728. [PMID: 26677855 PMCID: PMC4683064 DOI: 10.1371/journal.pgen.1005728] [Citation(s) in RCA: 95] [Impact Index Per Article: 10.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2015] [Accepted: 11/16/2015] [Indexed: 11/20/2022] Open
Abstract
We developed a new statistical framework to find genetic variants associated with extreme longevity. The method, informed GWAS (iGWAS), takes advantage of knowledge from large studies of age-related disease in order to narrow the search for SNPs associated with longevity. To gain support for our approach, we first show there is an overlap between loci involved in disease and loci associated with extreme longevity. These results indicate that several disease variants may be depleted in centenarians versus the general population. Next, we used iGWAS to harness information from 14 meta-analyses of disease and trait GWAS to identify longevity loci in two studies of long-lived humans. In a standard GWAS analysis, only one locus in these studies is significant (APOE/TOMM40) when controlling the false discovery rate (FDR) at 10%. With iGWAS, we identify eight genetic loci to associate significantly with exceptional human longevity at FDR < 10%. We followed up the eight lead SNPs in independent cohorts, and found replication evidence of four loci and suggestive evidence for one more with exceptional longevity. The loci that replicated (FDR < 5%) included APOE/TOMM40 (associated with Alzheimer’s disease), CDKN2B/ANRIL (implicated in the regulation of cellular senescence), ABO (tags the O blood group), and SH2B3/ATXN2 (a signaling gene that extends lifespan in Drosophila and a gene involved in neurological disease). Our results implicate new loci in longevity and reveal a genetic overlap between longevity and age-related diseases and traits, including coronary artery disease and Alzheimer’s disease. iGWAS provides a new analytical strategy for uncovering SNPs that influence extreme longevity, and can be applied more broadly to boost power in other studies of complex phenotypes. Longevity is a complex phenotype, and few genetic variants that affect lifespan have been identified. However, aging and disease are closely related, and a great deal is known about the genetic basis of disease risk. Here, we show using genome-wide association studies (GWAS) of longevity and disease that there is an overlap between loci involved in longevity and loci involved in several diseases, such as Alzheimer’s disease and coronary artery disease. We then develop a new statistical framework to find genetic variants associated with extreme longevity. The method, informed GWAS (iGWAS), takes advantage of knowledge from 14 large studies of disease and disease-related traits in order to narrow the search for SNPs associated with longevity. Using iGWAS, we found eight SNPs that are significant in our discovery cohorts, and we were able to validate four of these in replication studies of long-lived subjects. Our results implicate new loci in longevity and reveal a genetic overlap between longevity and age-related diseases and traits. Beyond the study of human longevity, iGWAS can be applied to boost statistical power in any GWAS of a target phenotype by using larger GWAS of genetically-related conditions.
Collapse
Affiliation(s)
- Kristen Fortney
- Department of Developmental Biology, Stanford University, Stanford, California, United States of America
- Department of Genetics, Stanford University, Stanford, California, United States of America
| | - Edgar Dobriban
- Department of Statistics, Stanford University, Stanford, California, United States of America
| | - Paolo Garagnani
- Department of Experimental, Diagnostic and Specialty Medicine Experimental Pathology, University of Bologna, Bologna, Italy
- Center for Applied Biomedical Research, St. Orsola-Malpighi University Hospital, Bologna, Italy
| | - Chiara Pirazzini
- Department of Experimental, Diagnostic and Specialty Medicine Experimental Pathology, University of Bologna, Bologna, Italy
- Interdepartmental Centre "L. Galvani" CIG, University of Bologna, Bologna, Italy
| | - Daniela Monti
- Department of Clinical, Experimental and Biomedical Sciences, University of Florence, Florence, Italy
| | - Daniela Mari
- Department of Medical Sciences, University of Milan, Milan, Italy
- Geriatric Unit, IRCCS Ca' Grande Foundation, Maggiore Policlinico Hospital, Milan, Italy
| | - Gil Atzmon
- Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, United States of America
| | - Nir Barzilai
- Department of Genetics, Albert Einstein College of Medicine, Bronx, New York, United States of America
| | - Claudio Franceschi
- Department of Experimental, Diagnostic and Specialty Medicine Experimental Pathology, University of Bologna, Bologna, Italy
- IRCCS, Institute of Neurological Sciences of Bologna, Bologna, Italy
| | - Art B. Owen
- Department of Statistics, Stanford University, Stanford, California, United States of America
| | - Stuart K. Kim
- Department of Developmental Biology, Stanford University, Stanford, California, United States of America
- Department of Genetics, Stanford University, Stanford, California, United States of America
- * E-mail:
| |
Collapse
|
133
|
Walsh KM, de Smith AJ, Hansen HM, Smirnov IV, Gonseth S, Endicott AA, Xiao J, Rice T, Fu CH, McCoy LS, Lachance DH, Eckel-Passow JE, Wiencke JK, Jenkins RB, Wrensch MR, Ma X, Metayer C, Wiemels JL. A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Res 2015; 75:4884-94. [PMID: 26527286 PMCID: PMC4651745 DOI: 10.1158/0008-5472.can-15-1105] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2015] [Accepted: 08/26/2015] [Indexed: 01/07/2023]
Abstract
Genome-wide association studies (GWAS) have identified SNPs in six genes that are associated with childhood acute lymphoblastic leukemia (ALL). A lead SNP was found to occur on chromosome 9p21.3, a region that is deleted in 30% of childhood ALLs, suggesting the presence of causal polymorphisms linked to ALL risk. We used SNP genotyping and imputation-based fine-mapping of a multiethnic ALL case-control population (Ncases = 1,464, Ncontrols = 3,279) to identify variants of large effect within 9p21.3. We identified a CDKN2A missense variant (rs3731249) with 2% allele frequency in controls that confers three-fold increased risk of ALL in children of European ancestry (OR, 2.99; P = 1.51 × 10(-9)) and Hispanic children (OR, 2.77; P = 3.78 × 10(-4)). Moreover, of 17 patients whose tumors displayed allelic imbalance at CDKN2A, 14 preferentially retained the risk allele and lost the protective allele (PBinomial = 0.006), suggesting that the risk allele provides a selective advantage during tumor growth. Notably, the CDKN2A variant was not significantly associated with melanoma, glioblastoma, or pancreatic cancer risk, implying that this polymorphism specifically confers ALL risk but not general cancer risk. Taken together, our findings demonstrate that coding polymorphisms of large effect can underlie GWAS "hits" and that inherited polymorphisms may undergo directional selection during clonal expansion of tumors.
Collapse
Affiliation(s)
- Kyle M Walsh
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California.
| | - Adam J de Smith
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
| | - Helen M Hansen
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California
| | - Ivan V Smirnov
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California
| | - Semira Gonseth
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
| | - Alyson A Endicott
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
| | - Jianqiao Xiao
- Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California
| | - Terri Rice
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California
| | - Cecilia H Fu
- Division of Hematology/Oncology, Children's Hospital Los Angeles, Los Angeles, California
| | - Lucie S McCoy
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California
| | - Daniel H Lachance
- Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - Jeanette E Eckel-Passow
- Division of Biomedical Statistics and Informatics, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - John K Wiencke
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, San Francisco, California
| | - Robert B Jenkins
- Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota
| | - Margaret R Wrensch
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, San Francisco, California
| | - Xiaomei Ma
- Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, Connecticut
| | - Catherine Metayer
- School of Public Health, University of California Berkeley, Berkeley, California
| | - Joseph L Wiemels
- Division of Neuroepidemiology, Department of Neurological Surgery, University of California, San Francisco, San Francisco, California. Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California. Institute for Human Genetics, University of California, San Francisco, San Francisco, California
| |
Collapse
|
134
|
Brenner DR, Amos CI, Brhane Y, Timofeeva MN, Caporaso N, Wang Y, Christiani DC, Bickeböller H, Yang P, Albanes D, Stevens VL, Gapstur S, McKay J, Boffetta P, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, Krokan HE, Skorpen F, Gabrielsen ME, Vatten L, Njølstad I, Chen C, Goodman G, Lathrop M, Vooder T, Välk K, Nelis M, Metspalu A, Broderick P, Eisen T, Wu X, Zhang D, Chen W, Spitz MR, Wei Y, Su L, Xie D, She J, Matsuo K, Matsuda F, Ito H, Risch A, Heinrich J, Rosenberger A, Muley T, Dienemann H, Field JK, Raji O, Chen Y, Gosney J, Liloglou T, Davies MPA, Marcus M, McLaughlin J, Orlow I, Han Y, Li Y, Zong X, Johansson M, Liu G, Tworoger SS, Le Marchand L, Henderson BE, Wilkens LR, Dai J, Shen H, Houlston RS, Landi MT, Brennan P, Hung RJ. Identification of lung cancer histology-specific variants applying Bayesian framework variant prioritization approaches within the TRICL and ILCCO consortia. Carcinogenesis 2015; 36:1314-26. [PMID: 26363033 PMCID: PMC4635669 DOI: 10.1093/carcin/bgv128] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Revised: 08/17/2015] [Accepted: 08/24/2015] [Indexed: 01/08/2023] Open
Abstract
Large-scale genome-wide association studies (GWAS) have likely uncovered all common variants at the GWAS significance level. Additional variants within the suggestive range (0.0001> P > 5×10(-8)) are, however, still of interest for identifying causal associations. This analysis aimed to apply novel variant prioritization approaches to identify additional lung cancer variants that may not reach the GWAS level. Effects were combined across studies with a total of 33456 controls and 6756 adenocarcinoma (AC; 13 studies), 5061 squamous cell carcinoma (SCC; 12 studies) and 2216 small cell lung cancer cases (9 studies). Based on prior information such as variant physical properties and functional significance, we applied stratified false discovery rates, hierarchical modeling and Bayesian false discovery probabilities for variant prioritization. We conducted a fine mapping analysis as validation of our methods by examining top-ranking novel variants in six independent populations with a total of 3128 cases and 2966 controls. Three novel loci in the suggestive range were identified based on our Bayesian framework analyses: KCNIP4 at 4p15.2 (rs6448050, P = 4.6×10(-7)) and MTMR2 at 11q21 (rs10501831, P = 3.1×10(-6)) with SCC, as well as GAREM at 18q12.1 (rs11662168, P = 3.4×10(-7)) with AC. Use of our prioritization methods validated two of the top three loci associated with SCC (P = 1.05×10(-4) for KCNIP4, represented by rs9799795) and AC (P = 2.16×10(-4) for GAREM, represented by rs3786309) in the independent fine mapping populations. This study highlights the utility of using prior functional data for sequence variants in prioritization analyses to search for robust signals in the suggestive range.
Collapse
Affiliation(s)
- Darren R Brenner
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada, Section of Genetics, International Agency for Research on Cancer, 69372 Lyon, France, Department of Cancer Epidemiology and Prevention Research, Cancer Control Alberta, Alberta Health Services, Calgary, Alberta T2T 5C7, Canada
| | - Christopher I Amos
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - Yonathan Brhane
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
| | - Maria N Timofeeva
- Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh EH8 9YL, UK
| | - Neil Caporaso
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Yufei Wang
- Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
| | - David C Christiani
- Departments of Environmental Health and Epidemiology, Harvard University School of Public Health, Boston, MA 02115, USA
| | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
| | - Ping Yang
- Division of Health Sciences, Cancer Center and College of Medicine, Mayo Clinic, Rochester, NY 55905, USA
| | - Demetrius Albanes
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Victoria L Stevens
- Epidemiology Research Program, American Cancer Society, Epidemiology and Surveillance Research, Atlanta, GA 30301, USA
| | - Susan Gapstur
- Epidemiology Research Program, American Cancer Society, Epidemiology and Surveillance Research, Atlanta, GA 30301, USA
| | - James McKay
- Section of Genetics, International Agency for Research on Cancer, 69372 Lyon, France
| | - Paolo Boffetta
- Population Sciences, Tisch Cancer Center and Institute for Translational Epidemiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - David Zaridze
- Institute of Carcinogenesis, Russian N.N.Blokhin Cancer Research Centre, 115478 Moscow, Russia
| | | | - Jolanta Lissowska
- Department of Epidemiology and Cancer Prevention, The M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw 02781, Poland
| | - Peter Rudnai
- National Institute of Environmental Health, Budapest 1097, Hungary
| | - Eleonora Fabianova
- Department of Health Risk Assessment, Regional Authority of Public Health, Banská Bystrica 97556, Slovak Republic
| | - Dana Mates
- National Institute of Public Health, Bucharest 050463, Romania
| | - Vladimir Bencko
- Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University in Prague, 128 00 Prague 2, Czech Republic
| | - Lenka Foretova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute, Brno 65653, Czech Republic
| | - Vladimir Janout
- Department of Preventive Medicine, Palacky University, Olomouc 77515, Czech Republic
| | - Hans E Krokan
- Department of Cancer Research and Molecular Medicine, Faculty of Medicine
| | - Frank Skorpen
- Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine and
| | - Maiken E Gabrielsen
- Department of Laboratory Medicine, Children's and Women's Health, Faculty of Medicine and
| | - Lars Vatten
- Department of Public Health and General Practice, Faculty of Medicine, Norwegian University of Science and Technology, Trondheim 7489, Norway
| | - Inger Njølstad
- Department of Community Medicine, University of Tromso, Tromso N-9037, Norway
| | - Chu Chen
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Gary Goodman
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA
| | - Mark Lathrop
- McGill University and Genome Québec Innovation Centre, Montréal, Quebec, Canada
| | - Tõnu Vooder
- Institute of Molecular and Cell Biology, University of Tartu, Tartu 51010, Estonia
| | - Kristjan Välk
- Department of Biomedicine, University of Bergen, Bergen 5009, Norway
| | - Mari Nelis
- Institute of Molecular and Cell Biology, Estonian Biocentre, Genotyping Core Facility, Tartu 51010, Estonia
| | - Andres Metspalu
- Institute of Molecular and Cell Biology, Estonian Biocentre, Genotyping Core Facility, Tartu 51010, Estonia
| | - Peter Broderick
- Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
| | - Timothy Eisen
- Department of Oncology, Cambridge Biomedical Research Centre, Cambridge CB2 0QQ, UK
| | - Xifeng Wu
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Di Zhang
- Department of Epidemiology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
| | - Wei Chen
- Department of Genetics, U.T. M.D. Anderson Cancer Center, Houston, TX 77030, USA
| | - Margaret R Spitz
- Duncan Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
| | - Yongyue Wei
- Departments of Environmental Health and Epidemiology, Harvard University School of Public Health, Boston, MA 02115, USA
| | - Li Su
- Departments of Environmental Health and Epidemiology, Harvard University School of Public Health, Boston, MA 02115, USA
| | - Dong Xie
- Division of Health Sciences, Cancer Center and College of Medicine, Mayo Clinic, Rochester, NY 55905, USA
| | - Jun She
- Division of Health Sciences, Cancer Center and College of Medicine, Mayo Clinic, Rochester, NY 55905, USA
| | - Keitaro Matsuo
- Department of Preventive Medicine, Kyushu University Graduate School of Medicine, Fukuoka City 819-0395, Japan
| | - Fumihiko Matsuda
- Center for Genomic Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8501, Japan
| | - Hidemi Ito
- Department of Epidemiology and Prevention, Aichi Cancer Center Research Institute, Chikusa-ku Nagoya 464-0021, Japan
| | - Angela Risch
- Division of Epigenomics and Cancer Risk Factors, DKFZ, 69121 Heidelberg, Germany, Division of Epigenomics and Cancer Risk Factors, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), 69121 Heidelberg, Germany
| | - Joachim Heinrich
- Unit of Environmental Epidemiology, Helmholtz Zentrum Munchen, 85764 Neuherberg, Germany
| | - Albert Rosenberger
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, 37073 Göttingen, Germany
| | - Thomas Muley
- Division of Epigenomics and Cancer Risk Factors, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), 69121 Heidelberg, Germany, Translational Research Unit and
| | - Hendrik Dienemann
- Division of Epigenomics and Cancer Risk Factors, Translational Lung Research Center Heidelberg (TLRC-H), German Center for Lung Research (DZL), 69121 Heidelberg, Germany, Department of Thoracic Surgery, Thoraxklinik am Universitätsklinikum Heidelberg, 69117 Heidelberg, Germany
| | - John K Field
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - Olaide Raji
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - Ying Chen
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - John Gosney
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - Triantafillos Liloglou
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - Michael P A Davies
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - Michael Marcus
- Roy Castle Lung Cancer Research Programme, The University of Liverpool Cancer Research Centre, Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK
| | - John McLaughlin
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
| | - Irene Orlow
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
| | - Younghun Han
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - Yafang Li
- Department of Community and Family Medicine, Center for Genomic Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH 03766, USA
| | - Xuchen Zong
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada
| | - Mattias Johansson
- Section of Genetics, International Agency for Research on Cancer, 69372 Lyon, France
| | - Geoffrey Liu
- Medical Oncology and Haematology, Department of Medicine, Princess Margaret Hospital, Toronto, Ontario M5G 2M9, Canada
| | - Shelley S Tworoger
- Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA, Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA
| | - Loic Le Marchand
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA
| | - Brian E Henderson
- Keck School of Medicine, University of South California, Los Angeles, CA 90089-0911, USA and
| | - Lynne R Wilkens
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI 96813, USA
| | - Juncheng Dai
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 210029, China
| | - Hongbing Shen
- Department of Epidemiology and Biostatistics, School of Public Health, Nanjing Medical University, Nanjing 210029, China
| | - Richard S Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK
| | - Maria T Landi
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
| | - Paul Brennan
- Section of Genetics, International Agency for Research on Cancer, 69372 Lyon, France
| | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Ontario M5T 3L9, Canada,
| |
Collapse
|
135
|
Hung RJ, Ulrich CM, Goode EL, Brhane Y, Muir K, Chan AT, Marchand LL, Schildkraut J, Witte JS, Eeles R, Boffetta P, Spitz MR, Poirier JG, Rider DN, Fridley BL, Chen Z, Haiman C, Schumacher F, Easton DF, Landi MT, Brennan P, Houlston R, Christiani DC, Field JK, Bickeböller H, Risch A, Kote-Jarai Z, Wiklund F, Grönberg H, Chanock S, Berndt SI, Kraft P, Lindström S, Al Olama AA, Song H, Phelan C, Wentzensen N, Peters U, Slattery ML, Sellers TA, Casey G, Gruber SB, Hunter DJ, Amos CI, Henderson B. Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. J Natl Cancer Inst 2015; 107:djv246. [PMID: 26319099 PMCID: PMC4675100 DOI: 10.1093/jnci/djv246] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2014] [Revised: 03/10/2015] [Accepted: 07/31/2015] [Indexed: 12/24/2022] Open
Abstract
BACKGROUND Inflammation has been hypothesized to increase the risk of cancer development as an initiator or promoter, yet no large-scale study of inherited variation across cancer sites has been conducted. METHODS We conducted a cross-cancer genomic analysis for the inflammation pathway based on 48 genome-wide association studies within the National Cancer Institute GAME-ON Network across five common cancer sites, with a total of 64 591 cancer patients and 74 467 control patients. Subset-based meta-analysis was used to account for possible disease heterogeneity, and hierarchical modeling was employed to estimate the effect of the subcomponents within the inflammation pathway. The network was visualized by enrichment map. All statistical tests were two-sided. RESULTS We identified three pleiotropic loci within the inflammation pathway, including one novel locus in Ch12q24 encoding SH2B3 (rs3184504), which reached GWAS significance with a P value of 1.78 x 10(-8), and it showed an association with lung cancer (P = 2.01 x 10(-6)), colorectal cancer (GECCO P = 6.72x10(-6); CORECT P = 3.32x10(-5)), and breast cancer (P = .009). We also identified five key subpathway components with genetic variants that are relevant for the risk of these five cancer sites: inflammatory response for colorectal cancer (P = .006), inflammation related cell cycle gene for lung cancer (P = 1.35x10(-6)), and activation of immune response for ovarian cancer (P = .009). In addition, sequence variations in immune system development played a role in breast cancer etiology (P = .001) and innate immune response was involved in the risk of both colorectal (P = .022) and ovarian cancer (P = .003). CONCLUSIONS Genetic variations in inflammation and its related subpathway components are keys to the development of lung, colorectal, ovary, and breast cancer, including SH2B3, which is associated with lung, colorectal, and breast cancer.
Collapse
Affiliation(s)
- Rayjean J Hung
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA).
| | - Cornelia M Ulrich
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Ellen L Goode
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Yonathan Brhane
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Kenneth Muir
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Andrew T Chan
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Loic Le Marchand
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Joellen Schildkraut
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - John S Witte
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Rosalind Eeles
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Paolo Boffetta
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Margaret R Spitz
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Julia G Poirier
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - David N Rider
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Brooke L Fridley
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Zhihua Chen
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Christopher Haiman
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Fredrick Schumacher
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Douglas F Easton
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Maria Teresa Landi
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Paul Brennan
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Richard Houlston
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - David C Christiani
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - John K Field
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Heike Bickeböller
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Angela Risch
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Zsofia Kote-Jarai
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Fredrik Wiklund
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Henrik Grönberg
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Stephen Chanock
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Sonja I Berndt
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Peter Kraft
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Sara Lindström
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Ali Amin Al Olama
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Honglin Song
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Catherine Phelan
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Nicholas Wentzensen
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Ulrike Peters
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Martha L Slattery
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Thomas A Sellers
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Graham Casey
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Stephen B Gruber
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - David J Hunter
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Christopher I Amos
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| | - Brian Henderson
- : Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada (RJH, YB, JGP); National Center for Tumor Diseases and German Cancer Research Center (DKFZ), Heidelberg, Germany (CMU, AR); Mayo Clinic, Rochester, MN (ELG, DNR); The University of Warwick, Coventry, UK (KM); Massachusetts General Hospital, Boston, MA (ATC); University of Hawaii Cancer Center, Honolulu, HI (LLM); Duke University, Durham, NC (JS); University of California at San Francisco, San Francisco, CA (JSW); Institute of Cancer Research, London, UK (RE, RH, ZKJ); Mount Sinai School of Medicine, New York, NY (PBo); Baylor College of Medicine, Houston, TX (MRS); Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS (BLF); Moffitt Cancer Center, Tampa, FL (ZC, CP, TAS); University of South California, Los Angeles, CA (CH, FS, GC, SBG, BH); Cambridge University, Cambridge, UK (DFE, AAAO, HS); National Cancer Institute, Bethesda, MD (MTL, SC, SIB, NW); International Agency for Research on Cancer, Lyon, France (PBr); Harvard School of Public Health, Boston, MA (DCC, PK, SL, DJH); University of Liverpool, Liverpool, UK (JKF); University of Göttingen, Medical School, Göttingen, Germany (HB); Karolinska Institutet, Stockholm, Sweden (FW, HG); Fred Hutchinson Cancer Research Center, Seattle, WA (UP); University of Utah Health Sciences Center and Huntsman Cancer Institute, Salt Lake City, UT (CMU, MLS); Geisel School of Medicine, Dartmouth College, Lebanon, NH (CIA)
| |
Collapse
|
136
|
Lack of association between the BIM deletion polymorphism and the risk of lung cancer with and without EGFR mutations. J Thorac Oncol 2015; 10:59-66. [PMID: 25384174 DOI: 10.1097/jto.0000000000000371] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
INTRODUCTION The BIM deletion polymorphism in intron 2 was found in a significant percent of the Asian population. Patients with epidermal growth factor receptor (EGFR) mutant lung cancers harboring this BIM polymorphism have shorter progression free survival and overall response rates to EGFR tyrosine kinase inhibitors. However, the association between the BIM deletion polymorphism and lung cancer risk is unknown. METHODS The BIM deletion polymorphism was screened by polymerase chain reaction in 765 lung cancer cases and 942 healthy individuals. RESULTS Carriers possessing one allele of the BIM polymorphism were observed in 13.0% of control cases and 12.8% of lung cancer cases, similar to incidence rates reported earlier in healthy individuals. Homozygote for the BIM polymorphism was observed in four of 942 healthy controls and three of 765 lung cancer cases. The frequency of the BIM deletion polymorphism in lung cancer patients was not related to age, sex, smoking history, or family history of lung cancer. The BIM deletion polymorphism was found in 30 of 212 patients with EGFR wild type lung cancers and 16 of 120 patients with EGFR mutant lung cancers. The frequency of the BIM polymorphism is similar between cancers with wild type EGFR and mutated EGFR (p = 0.78). CONCLUSION The BIM deletion polymorphism was not associated with lung cancer susceptibility. Furthermore, the BIM polymorphism is not associated with EGFR mutant lung cancer.
Collapse
|
137
|
Hancock DB, Reginsson GW, Gaddis NC, Chen X, Saccone NL, Lutz SM, Qaiser B, Sherva R, Steinberg S, Zink F, Stacey SN, Glasheen C, Chen J, Gu F, Frederiksen BN, Loukola A, Gudbjartsson DF, Brüske I, Landi MT, Bickeböller H, Madden P, Farrer L, Kaprio J, Kranzler HR, Gelernter J, Baker TB, Kraft P, Amos CI, Caporaso NE, Hokanson JE, Bierut LJ, Thorgeirsson TE, Johnson EO, Stefansson K. Genome-wide meta-analysis reveals common splice site acceptor variant in CHRNA4 associated with nicotine dependence. Transl Psychiatry 2015; 5:e651. [PMID: 26440539 PMCID: PMC4930126 DOI: 10.1038/tp.2015.149] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/26/2015] [Accepted: 08/19/2015] [Indexed: 01/04/2023] Open
Abstract
We conducted a 1000 Genomes-imputed genome-wide association study (GWAS) meta-analysis for nicotine dependence, defined by the Fagerström Test for Nicotine Dependence in 17 074 ever smokers from five European-ancestry samples. We followed up novel variants in 7469 ever smokers from five independent European-ancestry samples. We identified genome-wide significant association in the alpha-4 nicotinic receptor subunit (CHRNA4) gene on chromosome 20q13: lowest P=8.0 × 10(-9) across all the samples for rs2273500-C (frequency=0.15; odds ratio=1.12 and 95% confidence interval=1.08-1.17 for severe vs mild dependence). rs2273500-C, a splice site acceptor variant resulting in an alternate CHRNA4 transcript predicted to be targeted for nonsense-mediated decay, was associated with decreased CHRNA4 expression in physiologically normal human brains (lowest P=7.3 × 10(-4)). Importantly, rs2273500-C was associated with increased lung cancer risk (N=28 998, odds ratio=1.06 and 95% confidence interval=1.00-1.12), likely through its effect on smoking, as rs2273500-C was no longer associated with lung cancer after adjustment for smoking. Using criteria for smoking behavior that encompass more than the single 'cigarettes per day' item, we identified a common CHRNA4 variant with important regulatory properties that contributes to nicotine dependence and smoking-related consequences.
Collapse
Affiliation(s)
- D B Hancock
- Behavioral and Urban Health Program, Behavioral Health and Criminal Justice Research Division, Research Triangle Institute International, Research Triangle Park, NC, USA,Behavioral and Urban Health Program, Behavioral Health and Criminal Justice Research Division, Research Triangle Institute International, 3040 East Cornwallis Road, P.O. Box 12194, Research Triangle Park, NC 27709, USA. E-mail:
| | | | - N C Gaddis
- Research Computing Division, Research Triangle Institute International, Research Triangle Park, NC, USA
| | - X Chen
- Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA,Nevada Institute of Personalized Medicine and Department of Psychology, University of Nevada, Las Vegas, NV, USA
| | - N L Saccone
- Department of Genetics, Washington University in St. Louis, St. Louis, MO, USA
| | - S M Lutz
- Department of Biostatistics and Informatics, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - B Qaiser
- Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | - R Sherva
- Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA
| | | | - F Zink
- deCODE Genetics/Amgen, Reykjavik, Iceland
| | - S N Stacey
- deCODE Genetics/Amgen, Reykjavik, Iceland
| | - C Glasheen
- Behavioral and Urban Health Program, Behavioral Health and Criminal Justice Research Division, Research Triangle Institute International, Research Triangle Park, NC, USA
| | - J Chen
- Virginia Institute for Psychiatric and Behavioral Genetics, Department of Psychiatry, Virginia Commonwealth University, Richmond, VA, USA
| | - F Gu
- Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, United States Department of Health and Human Services, Bethesda, MD, USA
| | | | - A Loukola
- Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland
| | | | - I Brüske
- Institute of Epidemiology I, German Research Center for Environmental Health, Neuherberg, Germany
| | - M T Landi
- Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, United States Department of Health and Human Services, Bethesda, MD, USA
| | - H Bickeböller
- Department of Genetic Epidemiology, University of Göttingen—Georg-August University Göttingen, Göttingen, Germany
| | - P Madden
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | - L Farrer
- Department of Medicine (Biomedical Genetics), Boston University School of Medicine, Boston, MA, USA,Department of Neurology, Boston University School of Medicine, Boston, MA, USA,Department of Ophthalmology, Boston University School of Medicine, Boston, MA, USA,Department of Genetics and Genomics, Boston University School of Medicine, Boston, MA, USA,Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA,Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
| | - J Kaprio
- Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland,National Institute for Health and Welfare, Helsinki, Finland,Institute for Molecular Medicine, University of Helsinki, Helsinki, Finland
| | - H R Kranzler
- Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA,VISN 4 Mental Illness Research, Education and Clinical Center, Philadelphia VA Medical Center, Philadelphia, PA, USA
| | - J Gelernter
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA,Department of Genetics, Yale University School of Medicine, New Haven, CT, USA,Department of Neurobiology, Yale University School of Medicine, New Haven, CT, USA,VA CT Healthcare Center, Department of Psychiatry, West Haven, CT, USA
| | - T B Baker
- Center for Tobacco Research and Intervention, University of Wisconsin, Madison, WI, USA
| | - P Kraft
- Department of Epidemiology, Harvard University School of Public Health, Boston, MA, USA,Department of Biostatistics, Harvard University School of Public Health, Boston, MA, USA
| | - C I Amos
- Department of Community and Family Medicine, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH, USA,Department of Biomedical Data Science, Geisel School of Medicine at Dartmouth, Hanoven, NH, USA
| | - N E Caporaso
- Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, United States Department of Health and Human Services, Bethesda, MD, USA
| | - J E Hokanson
- Department of Epidemiology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
| | - L J Bierut
- Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA
| | | | - E O Johnson
- Fellow Program and Behavioral Health and Criminal Justice Research Division, Research Triangle Institute International, Research Triangle Park, NC, USA
| | - K Stefansson
- deCODE Genetics/Amgen, Reykjavik, Iceland,Faculty of Medicine, University of Iceland, Reykjavik, Iceland
| |
Collapse
|
138
|
Zhang C, Doherty JA, Burgess S, Hung RJ, Lindström S, Kraft P, Gong J, Amos CI, Sellers TA, Monteiro ANA, Chenevix-Trench G, Bickeböller H, Risch A, Brennan P, Mckay JD, Houlston RS, Landi MT, Timofeeva MN, Wang Y, Heinrich J, Kote-Jarai Z, Eeles RA, Muir K, Wiklund F, Grönberg H, Berndt SI, Chanock SJ, Schumacher F, Haiman CA, Henderson BE, Amin Al Olama A, Andrulis IL, Hopper JL, Chang-Claude J, John EM, Malone KE, Gammon MD, Ursin G, Whittemore AS, Hunter DJ, Gruber SB, Knight JA, Hou L, Le Marchand L, Newcomb PA, Hudson TJ, Chan AT, Li L, Woods MO, Ahsan H, Pierce BL. Genetic determinants of telomere length and risk of common cancers: a Mendelian randomization study. Hum Mol Genet 2015; 24:5356-66. [PMID: 26138067 PMCID: PMC4550826 DOI: 10.1093/hmg/ddv252] [Citation(s) in RCA: 117] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 06/03/2015] [Accepted: 06/25/2015] [Indexed: 11/29/2022] Open
Abstract
Epidemiological studies have reported inconsistent associations between telomere length (TL) and risk for various cancers. These inconsistencies are likely attributable, in part, to biases that arise due to post-diagnostic and post-treatment TL measurement. To avoid such biases, we used a Mendelian randomization approach and estimated associations between nine TL-associated SNPs and risk for five common cancer types (breast, lung, colorectal, ovarian and prostate cancer, including subtypes) using data on 51 725 cases and 62 035 controls. We then used an inverse-variance weighted average of the SNP-specific associations to estimate the association between a genetic score representing long TL and cancer risk. The long TL genetic score was significantly associated with increased risk of lung adenocarcinoma (P = 6.3 × 10(-15)), even after exclusion of a SNP residing in a known lung cancer susceptibility region (TERT-CLPTM1L) P = 6.6 × 10(-6)). Under Mendelian randomization assumptions, the association estimate [odds ratio (OR) = 2.78] is interpreted as the OR for lung adenocarcinoma corresponding to a 1000 bp increase in TL. The weighted TL SNP score was not associated with other cancer types or subtypes. Our finding that genetic determinants of long TL increase lung adenocarcinoma risk avoids issues with reverse causality and residual confounding that arise in observational studies of TL and disease risk. Under Mendelian randomization assumptions, our finding suggests that longer TL increases lung adenocarcinoma risk. However, caution regarding this causal interpretation is warranted in light of the potential issue of pleiotropy, and a more general interpretation is that SNPs influencing telomere biology are also implicated in lung adenocarcinoma risk.
Collapse
Affiliation(s)
| | | | | | - Rayjean J Hung
- Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, Canada
| | - Sara Lindström
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
| | - Peter Kraft
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
| | - Jian Gong
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Christopher I Amos
- Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Lebanon, NH, USA
| | - Thomas A Sellers
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | - Alvaro N A Monteiro
- Department of Cancer Epidemiology, H. Lee Moffitt Cancer Center, Tampa, FL, USA
| | | | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Angela Risch
- Division of Epigenomics and Cancer Risk Factors, DKFZ, German Cancer Research Center, Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - Paul Brennan
- International Agency for Research on Cancer, Lyon, France
| | - James D Mckay
- International Agency for Research on Cancer, Lyon, France
| | - Richard S Houlston
- Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK
| | - Maria Teresa Landi
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Public Health Service, Bethesda, MD, USA
| | | | - Yufei Wang
- Division of Genetics and Epidemiology, Institute of Cancer Research, Sutton, Surrey, UK
| | - Joachim Heinrich
- Institute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg, Germany
| | | | - Rosalind A Eeles
- The Institute of Cancer Research, Sutton, UK, Royal Marsden National Health Service (NHS) Foundation Trust, London and Sutton, UK
| | - Ken Muir
- Warwick Medical School, University of Warwick, Coventry, UK, Institute of Population Health, University of Manchester, Manchester, UK
| | - Fredrik Wiklund
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Henrik Grönberg
- Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm, Sweden
| | - Sonja I Berndt
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Public Health Service, Bethesda, MD, USA
| | - Stephen J Chanock
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, U.S. Public Health Service, Bethesda, MD, USA
| | - Fredrick Schumacher
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Christopher A Haiman
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Brian E Henderson
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California/Norris Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Ali Amin Al Olama
- Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - Irene L Andrulis
- Molecular Genetics/Laboratory Medicine and Pathobiology, Mount Sinai Hospital, University of Toronto, Toronto, Canada
| | - John L Hopper
- Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Australia
| | - Jenny Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Esther M John
- Cancer Prevention Institute of California, Fremont, CA, USA, Stanford University School of Medicine, Stanford, CA, USA
| | - Kathleen E Malone
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Marilie D Gammon
- Department of Epidemiology, University of North Carolina School of Public Health, Chapel Hill, NC, USA
| | - Giske Ursin
- Kreftregisteret, Cancer Registry of Norway, Oslo, Norway
| | | | - David J Hunter
- Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
| | - Stephen B Gruber
- USC Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
| | - Julia A Knight
- Ontario Cancer Genetics Network, Fred A. Litwin Center for Cancer Genetics, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada, Division of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada, Samuel Lunenfeld Research Institute, Mount Sinai Hospital, Toronto, ON, Canada
| | - Lifang Hou
- Department of Preventive Medicine, Northwestern University, Chicago, IL, USA
| | - Loic Le Marchand
- Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA
| | - Polly A Newcomb
- Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA, Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA
| | | | - Andrew T Chan
- Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA, Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA
| | - Li Li
- Department of Family Medicine and Community Health, Case Western Reserve University, Cleveland, OH, USA and
| | - Michael O Woods
- Discipline of Genetics, Faculty of Medicine, Memorial University, Newfoundland and Labrador, Canada
| | - Habibul Ahsan
- Department of Public Health Sciences, Center for Cancer Epidemiology and Prevention, Department of Medicine, Department of Human Genetics, The University of Chicago, Chicago, IL, USA
| | - Brandon L Pierce
- Department of Public Health Sciences, Center for Cancer Epidemiology and Prevention, Department of Human Genetics, The University of Chicago, Chicago, IL, USA,
| |
Collapse
|
139
|
Han S, Gao F, Yang W, Ren Y, Liang X, Xiong X, Pan W, Zhou L, Zhou C, Ma F, Yang M. Identification of an SCLC susceptibility rs7963551 genetic polymorphism in a previously GWAS-identified 12p13.33 RAD52 lung cancer risk locus in the Chinese population. Int J Clin Exp Med 2015; 8:16528-16535. [PMID: 26629180 PMCID: PMC4659068] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2015] [Accepted: 09/10/2015] [Indexed: 06/05/2023]
Abstract
As a well-known DNA repair gene, RAD52 plays an essential role in homologous recombination repair of double strand break, maintenance of genomic stability and prevention of cell malignant transformation. Previous genome-wide association studies (GWASs) have identified common genetic variants at 12p13.33 RAD52 locus associated with lung cancer risk in Caucasians. However, little or nothing has been known about the RAD52 single nucleotide polymorphisms (SNPs) in small cell lung cancer (SCLC) in the Chinese population. As a result, we examined the association between six RAD52 SNPs (rs10849605, rs1051669, rs10774474, rs11571378, rs7963551 and rs6489769) and SCLC susceptibility in Chinese. After 520 SCLC cases and 1040 controls in two independent case-control sets were genotyped, odds ratios (ORs) and 95% confidence intervals (CIs) were calculated by logistic regression. We found that only the RAD52 rs7963551 SNP was significantly associated with SCLC risk among six RAD52 SNPs genotyped. The odds of having the rs7963551 CA genotype in SCLC patients was 0.38 (95% CI = 0.24-0.62, P = 1.1×10(-4)) compared with the CC genotype. Stratified analyses of association between rs7963551 SNP and SCLC risk indicated that the functional polymorphism was only significantly associated with decreased risk among smokers but not nonsmokers. Our results demonstrated that the functional RAD52 rs7963551 SNP contributes to susceptibility to developing SCLC in the Chinese population.
Collapse
Affiliation(s)
- Sichong Han
- State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical TechnologyBeijing, China
| | - Feng Gao
- Health Division of Guard Bureau, General Staff Department of Chinese PLABeijing, China
| | - Wenjun Yang
- Oncology Department of Cancer Hospital & Institute, General Hospital, Ningxia Medical UniversityChina
| | - Yanli Ren
- State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical TechnologyBeijing, China
| | - Xue Liang
- State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical TechnologyBeijing, China
| | - Xiangyu Xiong
- State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical TechnologyBeijing, China
| | - Wenting Pan
- State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical TechnologyBeijing, China
| | - Liqing Zhou
- Clinical Laboratory, Shandong Cancer Hospital, Shandong Academy of Medical SciencesJinan, Shandong Province, China
| | - Changchun Zhou
- Department of Radiation Oncology, Huaian No. 2 HospitalHuaian, Jiangsu Province, China
| | - Fei Ma
- Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical SciencesBeijing, China
| | - Ming Yang
- State Key Laboratory of Chemical Resource Engineering, Beijing Laboratory of Biomedical Materials, College of Life Science and Technology, Beijing University of Chemical TechnologyBeijing, China
| |
Collapse
|
140
|
Fong KM, Daniels M, Goh F, Yang IA, Bowman RV. The current and future roles of genomics. Lung Cancer 2015. [DOI: 10.1183/2312508x.10009614] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
141
|
The SNP rs931794 in 15q25.1 Is Associated with Lung Cancer Risk: A Hospital-Based Case-Control Study and Meta-Analysis. PLoS One 2015; 10:e0128201. [PMID: 26079375 PMCID: PMC4469418 DOI: 10.1371/journal.pone.0128201] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2015] [Accepted: 04/24/2015] [Indexed: 01/11/2023] Open
Abstract
Background Lung cancer is one of the most common human malignant diseases and the leading cause of cancer death worldwide. The rs931794, a SNP located in 15q25.1, has been suggested to be associated with lung cancer risk. Nevertheless, several genetic association studies yielded controversial results. Methods and Findings A hospital-based case-control study involving 611 cases and 1062 controls revealed the variant of rs931794 was related to increased lung cancer risk. Stratified analyses revealed the G allele was significantly associated with lung cancer risk among smokers. Following meta-analysis including 6616 cases and 7697 controls confirmed the relevance of rs931794 variant with increased lung cancer risk once again. Heterogeneity should be taken into account when interpreting the consequences. Stratified analysis found ethnicity, histological type and genotyping method were not the sources of between-study heterogeneity. Further sensitivity analysis revealed that the study “Hsiung et al (2010)” might be the major contributor to heterogeneity. Cumulative meta-analysis showed the trend was increasingly obvious with adding studies, confirming the significant association. Conclusions Results from our current case-control study and meta-analysis offered insight of association between rs931794 and lung cancer risk, suggesting the variant of rs931794 might be related with increased lung cancer risk.
Collapse
|
142
|
Etokebe GE, Zienolddiny S, Kupanovac Z, Enersen M, Balen S, Flego V, Bulat-Kardum L, Radojčić-Badovinac A, Skaug V, Bakke P, Haugen A, Dembic Z. Association of the FAM46A gene VNTRs and BAG6 rs3117582 SNP with non small cell lung cancer (NSCLC) in Croatian and Norwegian populations. PLoS One 2015; 10:e0122651. [PMID: 25884493 PMCID: PMC4401550 DOI: 10.1371/journal.pone.0122651] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2014] [Accepted: 02/11/2015] [Indexed: 12/25/2022] Open
Abstract
We analyzed for associations between a variable number of tandem repeat (VNTR) polymorphism in the Family with sequence similarity 46, member A (FAM46A) gene and a single nucleotide polymorphism (rs3117582) in the BCL2-Associated Athanogene 6 (BAG6) with non small cell lung cancer in Croatian and Norwegian subjects. A total of 503 (262 Croatian and 241Norwegian) non small cell lung cancer patients and 897 controls (568 Croatian and 329 Norwegian) were analyzed. We found that the frequency of allele b (three VNTR repeats) of FAM46A gene was significantly increased in the patients compared to the healthy controls in the Croatian and the combined Croatian and Norwegian subjects. Genotype frequencies of cd (four and five VNTR repeats) and cc (four VNTR repeats homozygote) of the FAM46A gene were significantly decreased in the patients compared to the healthy controls in the Croatian and Norwegian subjects, respectively. Logistic regression analyses revealed FAM46A genotype cc to be an independent predictive factor for non small cell lung cancer risk in the Norwegian subjects after adjustment for age, gender and smoking status. This is the first study to suggest an association between the FAM46A gene VNTR polymorphisms and non small cell lung cancer. We found also that BAG6 rs3117582 SNP was associated with non small cell lung cancer in the Norwegian subjects and the combined Croatian-Norwegian subjects corroborating the earlier finding that BAG6 rs3117582 SNP was associated with lung cancer in Europeans. Logistic regression analyses revealed that genotypes and alleles of BAG6 were independent predictive factor for non small cell lung cancer risk in the Norwegian and combined Croatian-Norwegian subjects, after adjustment for age and gender.
Collapse
Affiliation(s)
- Godfrey Essien Etokebe
- Institute for Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway
- * E-mail:
| | - Shanbeh Zienolddiny
- Department of Chemical and Biological Working Environment, National Institute of Occupational Health, Oslo, Norway
| | - Zeljko Kupanovac
- Institute for Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway
- Section of Pulmology, Department of Internal Medicine, Clinical Hospital Center, University of Rijeka, Rijeka, Croatia
| | - Morten Enersen
- Institute for Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway
| | - Sanja Balen
- Institute for Transfusion Medicine, Clinical Hospital Center, University of Rijeka, Rijeka, Croatia
| | - Veljko Flego
- Section of Pulmology, Department of Internal Medicine, Clinical Hospital Center, University of Rijeka, Rijeka, Croatia
| | - Ljiljana Bulat-Kardum
- Section of Pulmology, Department of Internal Medicine, Clinical Hospital Center, University of Rijeka, Rijeka, Croatia
| | | | - Vidar Skaug
- Department of Chemical and Biological Working Environment, National Institute of Occupational Health, Oslo, Norway
| | - Per Bakke
- Department of Clinical Sciences, University of Bergen, Bergen, Norway
| | - Aage Haugen
- Department of Chemical and Biological Working Environment, National Institute of Occupational Health, Oslo, Norway
| | - Zlatko Dembic
- Institute for Oral Biology, Faculty of Dentistry, University of Oslo, Oslo, Norway
| |
Collapse
|
143
|
Wang Y, Wei Y, Gaborieau V, Shi J, Han Y, Timofeeva MN, Su L, Li Y, Eisen T, Amos CI, Landi MT, Christiani DC, McKay JD, Houlston RS. Deciphering associations for lung cancer risk through imputation and analysis of 12,316 cases and 16,831 controls. Eur J Hum Genet 2015; 23:1723-8. [PMID: 25804397 DOI: 10.1038/ejhg.2015.48] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2014] [Revised: 01/23/2015] [Accepted: 02/11/2015] [Indexed: 11/09/2022] Open
Abstract
Recent genome-wide association studies have identified common variants at multiple loci influencing lung cancer risk. To decipher the genetic basis of the association signals at 3q28, 5p15.33, 6p21.33, 9p21 and 12p13.33, we performed a meta-analysis of data from five genome-wide association studies in populations of European ancestry totalling 12 316 lung cancer cases and 16 831 controls using imputation to recover untyped genotypes. For four of the regions, it was possible to refine the association signal identifying a smaller region of interest likely to harbour the functional variant. Our analysis did not provide evidence that any of the associations at the loci being a consequence of synthetic associations rather than linkage disequilibrium with a common risk variant at these risk loci.
Collapse
Affiliation(s)
- Yufei Wang
- Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, Sutton, UK
| | - Yongyue Wei
- Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
| | - Valerie Gaborieau
- International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France
| | - Jianxin Shi
- Division of Cancer Epidemiology and Genetics, National Cancer institute, NIH, DHHS, Bethesda, MD, USA
| | - Younghun Han
- Department of Community and Family Medicine, Geisel School of Medicine, Center for Genomic Medicine, Lebanon, NH, USA
| | - Maria N Timofeeva
- International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France.,Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
| | - Li Su
- Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
| | - Yafang Li
- Department of Community and Family Medicine, Geisel School of Medicine, Center for Genomic Medicine, Lebanon, NH, USA
| | - Timothy Eisen
- Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK
| | - Christopher I Amos
- Department of Community and Family Medicine, Geisel School of Medicine, Center for Genomic Medicine, Lebanon, NH, USA
| | - Maria Teresa Landi
- Department of Health and Human Services, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD, USA
| | - David C Christiani
- Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA
| | - James D McKay
- International Agency for Research on Cancer (IARC, World Health Organization (WHO)), Lyon, France
| | - Richard S Houlston
- Division of Genetics and Epidemiology, The Institute of Cancer Research, Surrey, Sutton, UK
| |
Collapse
|
144
|
Delahaye-Sourdeix M, Oliver J, Timofeeva MN, Gaborieau V, Johansson M, Chabrier A, Wozniak MB, Brenner DR, Vallée MP, Anantharaman D, Lagiou P, Holcátová I, Richiardi L, Kjaerheim K, Agudo A, Castellsagué X, Macfarlane TV, Barzan L, Canova C, Thakker NS, Conway DI, Znaor A, Healy CM, Ahrens W, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Fabianova E, Mates IN, Bencko V, Foretova L, Janout V, Curado MP, Koifman S, Menezes A, Wünsch-Filho V, Eluf-Neto J, Boffetta P, Garrote LF, Serraino D, Lener M, Jaworowska E, Lubiński J, Boccia S, Rajkumar T, Samant TA, Mahimkar MB, Matsuo K, Franceschi S, Byrnes G, Brennan P, McKay JD. The 12p13.33/RAD52 locus and genetic susceptibility to squamous cell cancers of upper aerodigestive tract. PLoS One 2015; 10:e0117639. [PMID: 25793373 PMCID: PMC4368781 DOI: 10.1371/journal.pone.0117639] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Accepted: 12/29/2014] [Indexed: 11/18/2022] Open
Abstract
Genetic variants located within the 12p13.33/RAD52 locus have been associated with lung squamous cell carcinoma (LUSC). Here, within 5,947 UADT cancers and 7,789 controls from 9 different studies, we found rs10849605, a common intronic variant in RAD52, to be also associated with upper aerodigestive tract (UADT) squamous cell carcinoma cases (OR = 1.09, 95% CI: 1.04-1.15, p = 6x10(-4)). We additionally identified rs10849605 as a RAD52 cis-eQTL inUADT(p = 1x10(-3)) and LUSC (p = 9x10(-4)) tumours, with the UADT/LUSC risk allele correlated with increased RAD52 expression levels. The 12p13.33 locus, encompassing rs10849605/RAD52, was identified as a significant somatic focal copy number amplification in UADT(n = 374, q-value = 0.075) and LUSC (n = 464, q-value = 0.007) tumors and correlated with higher RAD52 tumor expression levels (p = 6x10(-48) and p = 3x10(-29) in UADT and LUSC, respectively). In combination, these results implicate increased RAD52 expression in both genetic susceptibility and tumorigenesis of UADT and LUSC tumors.
Collapse
Affiliation(s)
- Manon Delahaye-Sourdeix
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Javier Oliver
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Maria N. Timofeeva
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
- Colon Cancer Genetics Group, Institute of Genetics and Molecular Medicine, University of Edinburgh and Medical Research Council (MRC) Human Genetics Unit, Edinburgh, United Kingdom
| | - Valérie Gaborieau
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Mattias Johansson
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Amélie Chabrier
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Magdalena B. Wozniak
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Darren R. Brenner
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Maxime P. Vallée
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| | - Devasena Anantharaman
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - Pagona Lagiou
- Department of Hygiene, Epidemiology and Medical Statistics, University of Athens School of Medicine, Athens, Greece
| | - Ivana Holcátová
- Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lorenzo Richiardi
- University of Turin, Department of Medical Sciences, Unit of Cancer Epidemiology, Turin, Italy
| | | | - Antonio Agudo
- Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain
| | - Xavier Castellsagué
- Catalan Institute of Oncology-ICO, IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain
- CIBER Epidemiología y Salud Pública (CIBERESP), Madrid, Spain
| | | | | | - Cristina Canova
- Department of Environmental Medicine and Public Health, University of Padova, Padova, Italy
- MRC-HPA Centre for Environment and Health, Respiratory Epidemiology and Public Health, National Heart and Lung Institute, Imperial College, London, United Kingdom
| | - Nalin S. Thakker
- University of Manchester, School of Dentistry, Manchester, United Kingdom
| | - David I. Conway
- University of Glasgow Dental School, Glasgow, Scotland, United Kingdom
| | - Ariana Znaor
- Croatian National Cancer Registry, Croatian National Institute of Public Health, Zagreb, Croatia
| | | | - Wolfgang Ahrens
- Leibniz Institute for Prevention Research and Epidemiology—BIPS, Bremen, Germany
- Faculty of Mathematics and Computer Science, University of Bremen, Bremen, Germany
| | - David Zaridze
- Institute of Carcinogenesis, Cancer Research Centre, Moscow, Russian Federation
| | | | - Jolanta Lissowska
- Department of Cancer Epidemiology and Prevention, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland
| | | | - Ioan Nicolae Mates
- Saint Mary General and Esophageal Surgery Clinic, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
| | - Vladimir Bencko
- Institute of Hygiene and Epidemiology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic
| | - Lenka Foretova
- Department of Cancer Epidemiology and Genetics, Masaryk Memorial Cancer Institute and Masaryk University, Brno, Czech Republic
| | | | | | - Sergio Koifman
- National School of Public Health/FIOCRUZ, Rio de Janeiro, Brazil
| | - Ana Menezes
- Universidade Federal de Pelotas, Pelotas, Brazil
| | | | | | - Paolo Boffetta
- The Tisch Cancer Institute Mount Sinai School of Medicine, New York, NY, United States of America
| | | | - Diego Serraino
- Centro di Riferimento Oncologico, IRCSS, Unit of Epidemiology and Biostatistics, Aviano, Italy
| | - Marcin Lener
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Ewa Jaworowska
- Department of Otolaryngology and Laryngological Oncology, Pomeranian Medical University, Szczecin, Poland
| | - Jan Lubiński
- Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University, Szczecin, Poland
| | - Stefania Boccia
- Institute of Public Health, Section of Hygiene, Faculty of Medicine, Università Cattolica del Sacro Cuore, Rome, Italy
| | | | - Tanuja A. Samant
- Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| | - Manoj B. Mahimkar
- Cancer Research Institute, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre, Navi Mumbai, India
| | - Keitaro Matsuo
- Department of Health Promotion, Division of Oral Pathology, Kyushu Dental University, Kitakyushu, Japan
| | - Silvia Franceschi
- Infections and Cancer Epidemiology group (ICE), International Agency for Research on Cancer (IARC), Lyon, France
| | - Graham Byrnes
- Biostatistics group (BST), International Agency for Research on Cancer (IARC), Lyon, France
| | - Paul Brennan
- Genetic Epidemiology group (GEP), International Agency for Research on Cancer (IARC), Lyon, France
| | - James D. McKay
- Genetic Cancer Susceptibility group (GCS), International Agency for Research on Cancer (IARC), Lyon, France
| |
Collapse
|
145
|
Poirier JG, Brennan P, McKay JD, Spitz MR, Bickeböller H, Risch A, Liu G, Le Marchand L, Tworoger S, McLaughlin J, Rosenberger A, Heinrich J, Brüske I, Muley T, Henderson BE, Wilkens LR, Zong X, Li Y, Hao K, Timens W, Bossé Y, Sin DD, Obeidat M, Amos CI, Hung RJ. Informed genome-wide association analysis with family history as a secondary phenotype identifies novel loci of lung cancer. Genet Epidemiol 2015; 39:197-206. [PMID: 25644374 PMCID: PMC4554719 DOI: 10.1002/gepi.21882] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2014] [Revised: 12/02/2014] [Accepted: 12/02/2014] [Indexed: 01/05/2023]
Abstract
Lung cancer is the leading cause of cancer death worldwide. Although several genetic variants associated with lung cancer have been identified in the past, stringent selection criteria of genome-wide association studies (GWAS) can lead to missed variants. The objective of this study was to uncover missed variants by using the known association between lung cancer and first-degree family history of lung cancer to enrich the variant prioritization for lung cancer susceptibility regions. In this two-stage GWAS study, we first selected a list of variants associated with both lung cancer and family history of lung cancer in four GWAS (3,953 cases, 4,730 controls), then replicated our findings for 30 variants in a meta-analysis of four additional studies (7,510 cases, 7,476 controls). The top ranked genetic variant rs12415204 in chr10q23.33 encoding FFAR4 in the Discovery set was validated in the Replication set with an overall OR of 1.09 (95% CI=1.04, 1.14, P=1.63×10(-4)). When combining the two stages of the study, the strongest association was found in rs1158970 at Ch4p15.2 encoding KCNIP4 with an OR of 0.89 (95% CI=0.85, 0.94, P=9.64×10(-6)). We performed a stratified analysis of rs12415204 and rs1158970 across all eight studies by age, gender, smoking status, and histology, and found consistent results across strata. Four of the 30 replicated variants act as expression quantitative trait loci (eQTL) sites in 1,111 nontumor lung tissues and meet the genome-wide 10% FDR threshold.
Collapse
Affiliation(s)
- Julia G. Poirier
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Paul Brennan
- International Agency for Research on Cancer, Lyon, France
| | - James D. McKay
- International Agency for Research on Cancer, Lyon, France
| | | | - Heike Bickeböller
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Angela Risch
- Division of Epigenomics and Cancer Risk Factors, DKFZ, Heidelberg, Germany
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
| | - Geoffrey Liu
- Princess Margaret Hospital, Toronto, Ontario, Canada
| | - Loic Le Marchand
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America
| | - Shelley Tworoger
- Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, United States of America
- Channing Division of Network Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts, United States of America
| | | | - Albert Rosenberger
- Department of Genetic Epidemiology, University Medical Center, Georg-August-University Göttingen, Göttingen, Germany
| | - Joachim Heinrich
- Helmholtz Centre Munich, German Research Centre for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
| | - Irene Brüske
- Helmholtz Centre Munich, German Research Centre for Environmental Health, Institute of Epidemiology I, Neuherberg, Germany
| | - Thomas Muley
- Translational Lung Research Center Heidelberg (TLRC-H), Member of the German Center for Lung Research (DZL), Heidelberg, Germany
- Translational Research Unit, Thoraxklinik at the University of Heidelberg, Heidelberg, Germany
| | - Brian E. Henderson
- Department of Preventive Medicine, Keck School of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, United States of America
| | - Lynne R. Wilkens
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, Hawaii, United States of America
| | - Xuchen Zong
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| | - Yafang Li
- Dartmouth Medical College, Hanover, New Hampshire, United States of America
| | - Ke Hao
- Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
- Department of Respiratory Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
- Icahn Institute of Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | - Wim Timens
- Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - Yohan Bossé
- Institut universitaire de cardiologie et de pneumologie de Québec, Laval University, Québec, Canada
| | - Don D. Sin
- Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ma’en Obeidat
- Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | | | - Rayjean J. Hung
- Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada
| |
Collapse
|
146
|
Leng S, Liu Y, Weissfeld JL, Thomas CL, Han Y, Picchi MA, Edlund CK, Willink RP, Gaither Davis AL, Do KC, Nukui T, Zhang X, Burki EA, Van Den Berg D, Romkes M, Gauderman WJ, Crowell RE, Tesfaigzi Y, Stidley CA, Amos CI, Siegfried JM, Gilliland FD, Belinsky SA. 15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers. J Natl Cancer Inst 2015; 107:djv035. [PMID: 25713168 DOI: 10.1093/jnci/djv035] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
BACKGROUND Lung cancer is the leading cause of cancer-related mortality worldwide. Detection of promoter hypermethylation of tumor suppressor genes in exfoliated cells from the lung provides an assessment of field cancerization that in turn predicts lung cancer. The identification of genetic determinants for this validated cancer biomarker should provide novel insights into mechanisms underlying epigenetic reprogramming during lung carcinogenesis. METHODS A genome-wide association study using generalized estimating equations and logistic regression models was conducted in two geographically independent smoker cohorts to identify loci affecting the propensity for cancer-related gene methylation that was assessed by a 12-gene panel interrogated in sputum. All statistical tests were two-sided. RESULTS Two single nucleotide polymorphisms (SNPs) at 15q12 (rs73371737 and rs7179575) that drove gene methylation were discovered and replicated with rs73371737 reaching genome-wide significance (P = 3.3×10(-8)). A haplotype carrying risk alleles from the two 15q12 SNPs conferred 57% increased risk for gene methylation (P = 2.5×10(-9)). Rs73371737 reduced GABRB3 expression in lung cells and increased risk for smoking-induced chronic mucous hypersecretion. Furthermore, subjects with variant homozygote of rs73371737 had a two-fold increase in risk for lung cancer (P = .0043). Pathway analysis identified DNA double-strand break repair by homologous recombination (DSBR-HR) as a major pathway affecting susceptibility for gene methylation that was validated by measuring chromatid breaks in lymphocytes challenged by bleomycin. CONCLUSIONS A functional 15q12 variant was identified as a risk factor for gene methylation and lung cancer. The associations could be mediated by GABAergic signaling that drives the smoking-induced mucous cell metaplasia. Our findings also substantiate DSBR-HR as a critical pathway driving epigenetic gene silencing.
Collapse
Affiliation(s)
- Shuguang Leng
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Yushi Liu
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Joel L Weissfeld
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Cynthia L Thomas
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Younghun Han
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Maria A Picchi
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Christopher K Edlund
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Randall P Willink
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Autumn L Gaither Davis
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Kieu C Do
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Tomoko Nukui
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Xiequn Zhang
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Elizabeth A Burki
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - David Van Den Berg
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Marjorie Romkes
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - W James Gauderman
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Richard E Crowell
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Yohannes Tesfaigzi
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Christine A Stidley
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Christopher I Amos
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Jill M Siegfried
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Frank D Gilliland
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS)
| | - Steven A Belinsky
- : Lung Cancer Program, Lovelace Respiratory Research Institute, Albuquerque, NM (SL, YL, CLT, MAP, RPW, KCD, XZ, EAB, YT, SAB); Department of Epidemiology, Graduate School of Public Health (JLW) and Department of Medicine (TN, MR), University of Pittsburgh, Pittsburgh, PA; Center for Genomic Medicine, Department of Community and Family Medicine, Geisel School of Medicine, Dartmouth College, Hanover, NH (YH, CIA); Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA (CKE, DVDB, WJG, FDG); Department of Pharmacology & Chemical Biology, Hillman Cancer Center of the University of Pittsburgh Medical Center, Pittsburgh, PA (ALGD, JMS); Department of Internal Medicine, University of New Mexico, Albuquerque, NM (REC, CAS); Department of Pharmacology, University of Minnesota, Minneapolis, MN (JMS).
| |
Collapse
|
147
|
Wu Z, Wang P, Song C, Wang K, Yan R, Li J, Dai L. Evaluation of miRNA-binding-site SNPs of MRE11A, NBS1, RAD51 and RAD52 involved in HRR pathway genes and risk of breast cancer in China. Mol Genet Genomics 2015; 290:1141-53. [PMID: 25566853 DOI: 10.1007/s00438-014-0983-5] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2014] [Accepted: 12/24/2014] [Indexed: 01/02/2023]
Abstract
MiRNA-binding-site single nucleotide polymorphisms (SNPs) in homologous recombination repair (HRR) pathway genes may change DNA repair capacity and affect susceptibility to cancer though complex gene-gene and gene-reproductive factors interactions. However, these SNPs associated with breast cancer (BC) are still unclear in Chinese women. Therefore, we conducted a case-control study to evaluate the genetic susceptibility of the five miRNA-binding-site SNPs in HRR pathway genes (MRE11A rs2155209, NBS1 rs2735383, RAD51 rs963917 and rs963918 and RAD52 rs7963551) in the development of BC. MRE11A rs2155209 and RAD52 rs7963551 were found to be associated with BC risk (ORadjusted: 1.87; 95 % CI: 1.23-2.86 and ORadjusted: 0.36; 95 % CI: 0.24-0.58). NBS1 rs2735383, RAD51 rs963917 and rs963918 were associated with BC risk after stratification according to reproductive factors. Haplotypes of Crs963917Ars963918 decreased the risk of BC (ORadjusted: 0.53; 95 % CI: 0.4-0.68), while the Trs963917Ars963918 and Trs963917Grs963918 haplotypes could increase the risk of BC (ORadjusted: 1.28; 95 % CI: 1.05-1.57 and ORadjusted: 1.31; 95 % CI: 1.09-1.62). Combined effect of risk alleles showed that the five SNPs were associated with increased BC risk in a dose-dependent manner (P trend = 0.003). The GC genotype of rs2735383, AG + GG genotype of rs963918 and AC + CC genotype of rs7963551 were associated with PR positivity of BC patients. These findings suggest that the miRNA-binding-site SNPs involved in HRR pathway genes may affect susceptibility of BC in Chinese women; moreover, the interactions of gene-gene and gene-reproductive factors play vital roles in the progression of BC. Further functional studies with larger sample are needed to support and validate these findings.
Collapse
Affiliation(s)
- Zhenzhen Wu
- Department of Epidemiology and Statistics, College of Public Health, Zhengzhou University, Zhengzhou, 450001, Henan, People's Republic of China
| | | | | | | | | | | | | |
Collapse
|
148
|
Zhao J, Wang H, Hu W, Jin Y. Effect of HLA-B-associated transcript 3 polymorphisms on lung cancer risk: a meta-analysis. Med Sci Monit 2014; 20:2461-5. [PMID: 25430685 PMCID: PMC4259522 DOI: 10.12659/msm.891141] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
Abstract
Background The association between the HLA-B-associated transcript 3 polymorphisms and lung cancer risk is a subject of debate. We conducted a meta-analysis to evaluate the association between these polymorphisms and lung cancer susceptibility. Material/Methods A systematic search of electronic databases (PubMed, EMBASE, Wanfang, and China National Knowledge Infrastructure) was performed. Data were extracted and pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated. Results Ten case-control studies with 37 945 and 56 807 controls were included in this meta-analysis. Overall, a significant association between rs1052486 polymorphism and lung cancer susceptibility was observed (OR=1.07, 95% CI 1.01–1.12, P=0.01). In addition, a significant association was found for rs3117582 polymorphism (OR=1.29, 95% CI 1.22–1.37, P<0.01). Conclusions This meta-analysis suggested that HLA-B-associated transcript 3 polymorphisms are risk factors for lung cancer.
Collapse
Affiliation(s)
- Junfei Zhao
- Respiratory Department, The Sixth Affiliated Hospital of Wenzhou Medical University, People's Hospital, Lishui, China (mainland)
| | - Hongyuan Wang
- Respiratory Department, The Sixth Affiliated Hospital of Wenzhou Medical University, People's Hospital, Lishui, China (mainland)
| | - Weizhen Hu
- Respiratory Department, The Sixth Affiliated Hospital of Wenzhou Medical University, People's Hospital, Lishui, China (mainland)
| | - Yuanhong Jin
- Respiratory Department, The Sixth Affiliated Hospital of Wenzhou Medical University, People's Hospital, Lishui, China (mainland)
| |
Collapse
|
149
|
Abstract
Excess body weight and genetics play important roles in cancer susceptibility. Although several studies have reported on obesity and genetic variants as separate risk factors for cancer, very few studies have investigated the interaction between excess body weight and genetic variants in cancer susceptibility. In this review, we focus on the interplay between these 2 risk factors, which are a major determinant of the individual risk of cancer onset.
Collapse
|
150
|
Jin YX, Jiang GN, Zheng H, Duan L, Ding JA. Common genetic variants on 3q28 contribute to non-small cell lung cancer susceptibility: evidence from 10 case-control studies. Mol Genet Genomics 2014; 290:573-84. [PMID: 25344291 DOI: 10.1007/s00438-014-0934-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2014] [Accepted: 09/30/2014] [Indexed: 12/29/2022]
Abstract
The association between common variations (rs10937405, rs4488809) on 3q28 and lung cancer has been widely evaluated in various ethnic groups, since it was first identified through genome-wide association approach. However, the results have been inconclusive. To derive a more precise estimation of the relationship and the effect of factors that might modify the risk, we performed this meta-analysis. The random-effects model was applied, addressing heterogeneity and publication bias. A total of 10 articles involving 36,221 cases and 58,108 controls were included. Overall, the summary per-allele OR of 1.19 (95 % CI 1.14-1.25, P < 10(-5)) and 1.17 (95 % CI 1.10-1.23, P < 10(-5)) was found for the rs10937405 and rs4488809 polymorphisms, respectively. Significant results were also observed in heterozygous and homozygous when compared with wild genotype for these polymorphisms. Significant results were found in East Asians when stratified by ethnicity, whereas no significant associations were found among Caucasians. After stratifying by sample size, study design, control source and sex, significant associations were also obtained. In addition, our data indicate that these polymorphisms are involved in lung cancer susceptibility and confer its effect primarily in lung adenocarcinoma when stratified by histological subtype. Furthermore, significant associations were also detected both never-smokers and smokers for these polymorphisms. In conclusion, this meta-analysis demonstrated that rs10937405 and rs4488809 are a risk factor associated with increased non-small cell lung cancer susceptibility, particularly for East Asian populations.
Collapse
Affiliation(s)
- Yu-xing Jin
- Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji University, No. 507 Zhengmin Rd, Shanghai, 200433, People's Republic of China
| | | | | | | | | |
Collapse
|